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ABSTRACT 
Neonatal lupus erythematosus (NLE) affects neonates of Ro/SSA and La/SSB positive 
women. NLE is associated with several clinical manifestations including skin rash, 
cytopenia and congenital heart block (CHB). CHB is the most severe manifestation 
which can develop into a lethal atrioventricular (AV) block. There is a strong 
association between maternal Ro/SSA and La/SSB antibodies and development of 
CHB, but a recurrence rate of 20% in following pregnancies despite persisting maternal 
autoantibodies indicates that also other factors contribute to development of CHB.  
The aim of this thesis was to investigate transfer of autoantigen-specific 
immunoglobulins of different isotypes from the mother to the child, and the 
significance of the postnatal maternal Ro52-, p200-, Ro60- and La antibody levels in 
infants during their first year. Further, we aimed to identify factors other than 
autoantibodies influencing the fetal outcome in Ro52 positive pregnancy using 
experimental models. These studies were focused on investigating fetal susceptibility. 
Sera from Ro/SSA and La/SSB positive women and their children were 
analyzed by ELISA using purified, recombinant antigens and synthetic peptides. Ro52, 
Ro60 and La IgG antibodies all transferred from the mothers to their fetus in utero and 
were present in the infant at birth, but had decreased significantly in the infants at 4-5 
weeks of age. Little or no Ro/La specific IgM or IgA was present in the infants, and 
NLE developed independently of breastfeeding. We conclude that Ro/La 
autoantibodies are predominantly transferred to the child via the placenta, and that there 
appears to be no reason for a Ro/SSA positive mother to refrain from breast feeding.  
Using MHC congenic rat strains we show that heart block develops in rat pups 
of three strains carrying MHC haplotype RT1av1 (DA, PVG.AV1 and LEW.AV1) after 
maternal Ro52 immunization, while pups from LEW rats (RT1l) rarely developed 
block. Different anti-Ro52 antibody fine-specificities were generated in RT1av1 versus 
RT1l animals. Maternal and fetal influence was determined in an F2 cross between 
LEW.AV1 and LEW strains, which revealed higher susceptibility in RT1l than RT1av1 
pups once pathogenic Ro52-antibodies were present. This was further confirmed in that 
RT1l pups more frequently developed heart block than RT1av1 pups after passive 
transfer of RT1av1 anti-Ro52 sera, and by microarray analysis of fetal hearts that 
revealed increased expression of distinct MHC-encoded genes in RT1l compared to 
RT1av1 pups. Our findings suggest that generation of the pathogenic Ro52 antibodies is 
restricted by maternal MHC, and that a different set of genes encoded by the fetal MHC 
locus regulate susceptibility and determine the fetal disease outcome in anti-Ro52 
positive pregnancies. 
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LIST OF ABBREVIATIONS 
 
ANA anti-nuclear antibodies 
AVB atrioventricular block 
CFA complete Freund’s adjuvant 
CHB Congenital heart block 
CIA collagen-induced arthritis 
dsDNA double-stranded deoxyribonucleic acid 
EAE experimental autoimmune encephalomyelitis 
ECG Electrocardiogram 
ELISA enzyme-linked immunosorbent assay 
hYRNA human y ribonucleic acid 
HLA human leukocyte antigen 
Ig 
i.p. 
Immunoglobulin 
intraperitoneal 
MaBP maltose binding protein 
MHC major histocompatibility complex 
NLE Neonatal lupus erythematosus 
pSS primary Sjögren’s syndrome 
RF rheumatoid factor 
RBCC RING/B-box/coiled-coil 
RNP Ribonucleoprotein 
s.c. Subcutaneous 
SLE Systemic lupus erythematosus 
SS Sjögren’s syndrome 
ssDNA single stranded deoxyribonucleic acid 
Sm 
TGFβ 
TNFα 
Smith antigen 
Transforming growth factor beta 
Tumor necrosis factor alpha 
TRIM 
TCRBV 
Tripartite motif 
T cell receptor B variable 
U1nRNP anti-nuclear ribonucleoprotein 
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1 INTRODUCTION 
Our immune system has an ingenious ability to distinguish between what is body 
derived and what is harmful infectious agents like virus or bacteria. But, at certain 
occasions the immune system lose its tolerance to the body it is meant to protect and 
autoimmunity develops. In the worst case this may lead to the progress of an 
autoimmune disease. About 4-5% of the population is affected by an autoimmune 
disease (Naparstek 1993, Wandstrat 2001) and in general, the autoimmune disease 
incidence is higher in females compared to men (Lockshin 2006). The cause of this 
sex difference has been suggested to be due to sex hormones (Whitacre 2001), and 
the X chromosome has also been implicated (Invernizzi 2005, Selmi 2006) as well as 
that fetal-maternal (maternal-fetal) microchimerism may be of significance (Gleicher 
2007). 
Autoimmune diseases can be divided into cell-specific, organ-specific and systemic 
disease (Bach 1995). Rheumatic diseases is a large group of chronic inflammatory 
conditions with autoimmune features and a broad diversity of immunological 
manifestations. The following text will mainly focus on two rheumatic systemic 
conditions: Systemic lupus erythematosus (SLE) and Sjögren’s syndrome (SS). 
 
1.1 SYSTEMIC LUPUS ERYTHEMATOSUS & SJÖGREN’S SYNDROME 
Systemic lupus eryhematosus is a condition with many clinical and immunological 
manifestations, usually including inflammation and depositions of autoantibodies and 
immunocomplexes in multiple organs (Klippel 1997). The autoantibodies in SLE are 
directed towards ubiquitous autoantigens, and virtually any organ can be affected and 
many different symptoms and manifestations may occur in skin and mucous 
membranes, central nervous-, musculoskeletal-, cardiovascular-, respiratory-, 
abdominal- and renal systems and the eyes (Isenberg 2005). The cause of SLE 
development is thought to be due to a combination of susceptiblity genes and 
environmental factors. SLE mainly affects women - the female versus male ratio is 
9:1. In addition, women are predominantly affected by SLE during their most fertile 
period, suggesting influence of disease development by hormonal factors (Petri 
2002). 
Patients may be diagnosed with either primary Sjögren’s syndrome (pSS) and then 
occurs without any associated autoimmune disease or secondary Sjögren’s syndrome 
(SS) when the syndrome coexist with another autoimmune disease. Characteristic signs 
of SS are destroyed and dysfunctional exocrine glands and deposits of lymphocytic 
infiltrates recognized as dryness in mouth and eyes, also described as sicca symptoms 
(Ramos-Casals 2007, Jonsson 2000). Typical symptoms for SS are fatigue, general 
malaise, low grade fever, myalgias and arthralgias. The prevalence of SS is between 
0,1% and 3% depending on what classification criteria is used (Fox 1986, Jacobsson 
1989, Bjerrum 1997, Dafni 1997, Gran 2002, Ramos-Casals 2007). 
 
1.2 B CELLS, MHC CLASS II, AUTOANTIBODIES 
There are two classes of MHC molecules: MHC class I molecules that collect peptides 
derived from proteins synthesized in the cytosol for cell surface presentation and MHC 
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class II molecules that bind and present peptides derived from proteins in intracellular 
vesicles such as macrophage vesicles or peptides internalized by phagozytic cells and B 
cells. The essential helper T cell recognizes the complex of bound antigenic peptide 
with the MHC class II molecule and activates the B cell, and the B cell can proliferate 
and differentiate into antibody producing plasma cells (Figure 1). 
 
 
 
Figure 1. Antigen presentation by the MHC class II complex. The B cell is activated 
when T cell recognizes the antigen peptide MHC class II complex (A). The antigen 
recognition induces B cell proliferation (B) and differentiation to antibody-secreting 
plasma cells (C). 
 
Unfortunately, sometimes the protective immune system lose its ability to just defend 
the body, but instead attack its protégé i.e. autoimmunity is developed. In autoimmune 
rheumatic diseases antibodies towards self antigens are developed – autoantibodies 
(Janeway 2001). 
Important mediator molecules in the implication of immunology and autoimmunity are 
the so-called cytokines. The roles of cytokines are essential for immune cell 
development, immunoregulation and immune effector functions. Still there is much to 
understand in their role in autoimmunity. Increasing evidence support the fact that 
cytokines do not just function as either pro-inflammatory, inducing autoimmunity, or 
anti-inflammatory, suppressing autoimmunity. The cytokines seems to have a 
complicated role were combinations of cytokines exert variable effects during the 
development of an autoimmune disease. The cytokine interferon (IFN) is an example of 
giving such a pleiotropic effect on autoimmunity (O’Shea 2002). 
An important cytokine in SS and SLE development and progression is IFNα 
(Bengtsson 2000, Båve 2005). 
 
1.3 IMMUNOGLOBULIN ISOTYPES AND SUBCLASSES 
The immunoglobulin (Ig) or antibodies are divided into five classes, IgA, IgD, IgE, IgG 
and IgM. IgA is secreted in saliva, breast milk and the intestine. The main role of IgD is 
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unknown besides that IgD and surface bound IgM represent the B cell receptor. IgG is 
the antibody isotype found in the circulation after antigen stimulation. During 
pregnancy IgG antibodies may transfer via active transport facilitated by Fc receptors 
into the fetal circulation. IgG antibodies are divided in four subclasses: IgG1, IgG2, 
IgG3 and IgG4. 
 
1.4 AUTOANTIBODIES IN SLE AND SS 
Different kinds of autoantibodies are associated with and may be found in the sera of 
both SLE and Sjögren’s syndrome patients, but these autoantibodies may also be found 
in sera of patients with other diagnoses. Examples of autoantibodies found in SLE or 
SS patients are: rheumatoid factor (RF), which binds to the Fc region of IgG and anti-
nuclear antibodies (ANA) with affinity to different intracellular antigens as anti-
dsDNA, anti-ssDNA, anti-Sm (only SLE), anti-SSA/Ro (Ro52/Ro60), anti-SSB/La, 
and anti-U1RNP (only SLE). ANA is an important diagnostic tool in SLE and SS 
(Griesmacher 2001). 
 
1.5 RO52, RO60 AND LA 
Ro/SSA and La/SSB proteins exist in all cells both in humans and mammals. These 
intracellular proteins bind/interact with hYRNA and together make a cytoplasmatic 
ribonucleoprotein (RNP) complex. It is not clarified what role this complex has or 
what function the complex associated proteins have. 
 
1.5.1 La/SSB 
There are studies suggesting that the La protein may have a function in transcriptation 
termination (Wolin 2002). In addition, La might be involved in virus replication, and 
play a key role in the induction of the immune system reaction against the RNP 
complex. This reaction is thought to be the source of a mechanism were the reaction 
against the La protein is followed by epitope spreading within the complex (Topfer 
1995, Tseng 1997). 
 
1.5.2 Ro/SSA 
The Ro/SSA antigens consist of the non-homologous proteins Ro52 and Ro60. Ro60  
functions in a discard pathway of defect 5SrRNA (O’Brian 1994, Labbe 1999). Animal 
studies on mice without Ro60 (Ro60-/-) show symptoms similar to lupus together and 
develop autoantibodies (Xue 2003). Ro52 consists of 475 aa and belongs to the family 
RING/B-box/coiled-coil (RBCC) or tripartite motif proteins (TRIMS) (Reymond 2001) 
(Figure 2). 
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Figure 2. The common structure of the TRIM/RBCC proteins. The Ro52 protein 
consists of a RING finger, a B-box motif and a coiled-coil region. 
 
The exact function/role for Ro52 is still not completely revealed, but a previous study 
suggests that Ro52 is an E3 ligase involved in the regulation of proliferation and cell 
death (Espinosa 2006). There are also results showing that the RING finger and B box 
domains are important in protein-protein interactions and it is common that 
ubiquitinating enzymes contain RING fingers (Joazeiro 2000). The coiled-coil region 
consists of a leucine zipper, a leucine rich alpha helix with a leucine positioned as every 
seventh amino acid in the polypeptide chain. This means that a leucine is pointing 
towards the same direction at each second turn in the helix, which is of significance due 
to its function in protein-protein interaction (Paris 2003). Ro52 is predominantly 
located in the cytoplasm, but may also be found in the nucleus, and has been suggested 
to shuttle between the two compartments (Simons 1994, Keech 1995, Pourmand 1998, 
Ohlsson 2002, Pourmand 1998). The Ro52 protein has also been associated to a 
regulating role in the transcription process (Wang 2001), but more recently was 
reported to downregulate activity of IRF transcription factors via ubiquitinations (Kong 
2007, Higgs 2008, Espinosa 2009). Interestingly, Ro52 knockout mice develop tissue 
inflammation and systemic autoimmunity mediated by the IL-23/Th17 pathway 
(Espinosa 2009).  
Since Ro52 is an intracellular protein it is a puzzle how it is initially 
exposed to the immune system with a following tolerance loss and auto-antibody 
development. Different proposals to the responsible mechanism have been suggested 
such as: cell stress via ultraviolet radiation (Zhang 2000, Saegusa 2002) or apoptosis 
followed by exposed intracellular proteins (Ohlsson 2002). There are also results 
showing that hormones like estradiol influence Ro52 expression (Wang 1996, Sakabe 
1998, Zhang 2000), and that hormones together with ultraviolet radiation have a 
synergistic effect on Ro52 expression (Jones 1992). Furthermore, it has been shown 
that Ro52, besides association with the Ro/La RNP complex, binds to the heavy chain 
of immunoglobulin G (IgG) (Yang 1999, Rhodes 2002) and that calreticulin, a 
multifunctional intracellular protein, interacts with Ro52 (Cheng 1996). 
In trials aimed to decide/define the autoantibody epitope on Ro52, it has been shown 
that the leucine zipper domain has a central role (Blange 1994, Buyon 1994, McCauliff 
1994, Kato 1995, Dörner 1996) and results with synthetic peptides, overlapping the 
leucine zipper region, revealed that maternal Ro52 autoantibodies had a strong affinity 
to a peptide corresponding to aa 200-239, denoted p200; demonstrating a serologic 
marker for fetal risk of CHB (Salomonson 2002). 
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1.6 THE RO/SSA AND LA/SSB AUTOANTIGENS IN HEART BLOCK 
Maternal Ro/SSA-La/SSB autoantibodies are supposed to bind a cross-reactive self-
antigen on cardiomyocytes. Still no definite target for those antibodies has been 
identified, but different targets in cardiac tissue have been suggested such as α1C and 
α1D subunits of the L-type calcium channel (Boutjdir 2000, Qu 2005, Hu 2004), the T-
type calcium channel (Hu 2004) and the atrial 5-HT4 receptor (Eftekhari 2000, 
Eftekhari 2001, Kamel 2005).   
 
1.7 SLE AND SS IMPLICATION DURING PREGNANCY 
SLE and SS may be diagnosed at any age, but it is common among women that SLE 
has its onset during the child-bearing years (Petri 2002) and SS mainly develop at 30-
50 years of age (Jonsson 2000), which indicates a close hormonal association. 
Pregnancy among the anti-SSA/Ro-SSB/La positive women is commonly associated 
with different kinds of complications such as renal involvement, proteinuria and 
preterm delivery (Alshohaib 2009, Wagner 2009). Studies indicate that regardless of 
symptomatic condition, lupus increases the fetal, neonatal and maternal risk during 
pregnancy. Even in inactive SLE, there is still an increased risk of complications during 
pregnancy (Alshohaib 2009, Wagner 2009). Other studies however do not show further 
complications besides CHB development of anti-SSA/Ro antibodies affecting the 
pregnancy outcomes (Brucato 2002). 
 
1.8 NEONATAL LUPUS ERYTHEMATOSUS (NLE) 
Neonatal lupus erythematosus is a passively transferred condition that influences the 
fetus. NLE includes numerous kinds of manifestations but the most common of NLE 
manifestations are skin rash and CHB. Other symptoms are cytopenias and liver 
involvment (Buyon 1998). The incidence of NLE is about 1-2% of children to mothers 
with SLE, and 15-20% of children to mothers diagnosed with SLE and Ro/SSA 
antibodies but also occurrs in the children of asymptomatic women (Spence 2006, 
Jaeggi 2005). Maternal Ro/La autoantibodies are strongly associated to the 
development of congenital heart block (CHB), which is the most serious condition of 
neonatal lupus erythematosus (McCauliffe 1995, Dörner 2000). About 50% of the NLE 
infants develop CHB (Lee 1990) and the condition is irreversible and fatal in its worst 
state. Apart from CHB, NLE symptoms are transient and the symptoms decline in 
parallel with the maternal antibody levels in the neonate circulation, and are dissolved 
approximately 6-8 months after delivery (Lee 1994). 
There are studies suggesting different factors such as human leukocyte antigen (HLA) 
haplotypes, autoantibodies and isotype specificity as determining NLE symptom 
development in the infant (Kim 2001). It has also been suggested that CHB is 
predominantely correlated to Ro52 antibodies and that the transient conditions of NLE 
correlates with Ro60 antibodies (Lee 1994). 
 
1.9 ELECTROCARDIOGRAM (ECG) INTERPRETATION 
An electrocardiogram (ECG) consists of a P wave, a PR interval, a QRS wave, ST 
segment, T wave, QT interval, and possibly a U wave. The P wave represents 
activation of the atrium. The QRS complex signifies the ventricular depolarization and 
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the T wave (as well as the U wave) corresponds to the ventricular repolarization. The 
PR interval is measured from the P wave onset to the beginning of the QRS complex 
(Figure 3). 
 
 
 
 
1.10 CONGENITAL HEART BLOCK (CHB) 
Congenital heart block is a lethal condition with conduction abnormalities in a 
structurally normal heart (Buyon 2003), which develops in fetuses of Ro/SSA and 
La/SSB positive women. The mothers can be diagnosed with rheumatic diseases such 
as SLE and SS but may even be asymptomatic. Ro/SSA women have a 2% risk getting 
a child with CHB and the risk is about 20% among women who previously have had a 
child with CHB (Michaelson 1972, Julkunen 2001, Brucato 2001, Buyon 2009). 
 
1.10.1 The three types of AV block 
Congenital heart block is a condition with a disorder of the conduction system with an 
affected atrioventricular node in the fetal heart (John 2004). The congenital heart block  
which is hypothesized to develop via three stages, from a reversible first state with 
conduction prolongations to a third irreversible state with no conduction between the 
atria and the ventricles (Sonesson 2004). CHB is divided into AVB type I, AVB type II 
and AVB type III according to the severity grade. The three severity conditions can be 
distinguished as: AV block type I, which is the reversible state seen as a prolonged PR 
interval, AV block type II which is characteristic on the electrocardiogram (ECG) 
expressing absence of some conducted impulses through the AV node, and thus 
disappearance of some QRS complexes. AV block type II is also subdivided into three 
variations: 1) Type I (Wenckeback) second-degree AV block expressing a lengthening 
of the AV conduction before it is blocked, 2) Type II (Mobitz II) second-degree AV 
block is included by an abrupt or sporadic block without a preceding lengthening of the 
AV conduction time, 3) 2:1 AV block with a conduction of every second impulse 
through the AV node. In AV block type III there is no conducted impulses through the 
AV node at all, and this lethal condition demands a life-long pacemaker dependence 
(John 2004, Jaeggi 2005, Dubin 2003). 
 
Figure 3. ECG showing the P, Q, 
R, S and T waves. PR 
prolongation and observation of 
missing QRS complexes in the 
ECG indicate AV block. 
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1.10.2 Incidence 
The frequency of CHB in the population is 1/15 000 to 1/20 000 live births  
(Michaelsson 1972). CHB is most commonly detected between 18-24 weeks of 
gestation (Brucato 2001). Women positive to anti-Ro/SSA antibodies may therefore be 
examined by Doppler echocardiography every 2 weeks with start from the 16th week of 
gestational age. In that way there is an increased chance to detect early changes to the 
cardiac conduction that may develop into a complete atrioventricular block (AVB). 
There is today no available prophylactic therapy, but early detected conduction 
abnormalities might be treated with fluorinated steroids (Brucato 2008). There are 
different techniques available to survey and evaluate changes in fetal cardiac time 
intervals.    
 
1.10.3 Cardiac pathology of congenital heart block 
Histological investigations of the conduction system in fetal hearts have shown 
inflammation with deposits of antibodies, complement components and lymphocytic 
infiltrates with a developed calcification and fibrosis leading to imperfect signal 
conduction (Litsey 1985, Lee 1987, Clancy 2004). It has been suggested that 
macrophages have a major role in the sustained inflammatory reaction and fibrotic 
development because of a shift to a state of hypersecretion of proinflammatory 
cytokines such as TNFα (Miranda-Carus 2000). The fibrosis development observed in 
histologic samples is also believed to be dependent on TGFβ – a pro-fibrotic cytokine – 
secreted by macrophages (Clancy 2003). In addition, it is also suggested that 
macrophages increase the calcification in tissue by secreting alkaline phosphatase 
(Tintut 2002). Maternal myocardial cells have been found in fetal hearts of patients 
with NLS-CHB, and these findings are suggested to be an additional factor involved in 
the pathogenesis or progression of CHB (Stevens 2005). 
 
1.11 BREAST-FEEDING AND MATERNAL AUTOANTIBODIES 
The host defence is not fully developed in the new-born child, and transferred maternal 
antibodies are important in the fetal humoral defence. During the time in utero maternal 
IgG antibodies are transferred into the fetal circulation via placenta, and after birth the 
fetus is supplemented by secretory IgA in breast-milk (Hanson LÅ 2007). Also IgM is 
trasfered via the breast milk. 
 
1.12 GENES INFLUENCE IN AUTOIMMUNITY 
The autoimmune disease are chronic conditions associated with a reactive humoral 
and/or cellular immune system due to initial loss of tolerance to self antigens. In 
addition, besides the immunological reaction, it has been shown that the genetic 
background is of considerable importance due to disease susceptibility and there are 
associations with human leukocyte antigen (HLA)/major histocompatibility complex 
(MHC) and with non-HLA/non-MHC genes. The MHC gene region has a dominating 
role influencing the development of autoimmune diseases, but there is also a strong 
relation between chromosomal non-MHC regions and autoimmune disease. The region 
is divided into MHC class I, class II and class III (Ghodke 2005, Serrano 2006). The 
MHC complex is a gene dense region, located on human chromosome 6p12.31, 
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covering more than 120 expressed genes (1999). The corresponding MHC region in 
rats is called RT1 and is located on chromosome 20 (RN020). Besides the strong 
association of MHC-genes and autoimmunity, there are also non-MHC genes 
associated to autoimmune diseases which include Cytotoxic T lymphocyte associated 
antigen 4 (CTLA4), Protein tyrosine phosphatase (PTPN22) and Tumor necrosis 
factor-α (TNFα).  
Despite the strong association between maternal anti-Ro/SSA-La/SSB autoantibodies 
and CHB development, the risk is still relative low with its 2 %, which today makes it 
almost impossible to make a prospective prediction of the pregnancy outcome. Even 
women with a second pregnancy and a previous child with CHB are difficult to predict 
because 80% will deliver a baby without CHB. Today there are no suitable screening 
markers to apply in purpose preventing development of CHB. Due to the relative low 
incidence of CHB it is assumed that besides maternal autoantibodies also the fetal 
genetic background determines the susceptibility of AV-block development. 
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2 AIMS OF THE THESIS 
Women positive for anti-Ro/SSA and La/SSB autoantibodies may risk getting a child 
with NLE, which in the worst case develops into an irreversible heart failure – 
congenital heart block (CHB). The heart block inducing autoantibodies are transferred 
to the fetus during pregnancy and affect the developing heart. A subsequent fetus may 
however not be affected, despite the presence of maternal autoantibodies. This indicates 
that there are additional, yet unidentified, factors critical for development of congenital 
heart block.  
 
Based on these observations, the aim of my thesis project was 
 
• To investigate Ro/SSA and La/SSB autoantibodies in congenital heart block. 
• To identify additional factors contributing to development of congenital heart 
block. 
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3 RESULTS AND DISCUSSION 
The strong association between anti-Ro/SSA-La/SSB antibodies and CHB is well 
known, but it is still not fully clarified what underlying pathogenic mechanism cause 
CHB development. It is well confirmed that maternal IgG autoantibodies against 
Ro/SSA-La/SSB antigen are transferred from the mother to the child via the placenta 
during pregnancy and that women with anti-Ro/SSA-La/SSB-antibodies have a risk of 
getting a child with NLE (Michaelsson 1972, Scott 1983, Ramsey-Goldman 1986, Lee 
1990, Manthorpe 1992, Waltuck 1994, Brucato 2001). Because the incidence of CHB 
among children to Ro/SSA and La/SSB positive mothers is comparatively low and that 
surveillance of Ro/SSA La/SSB positive pregnancies for potential development of 
complete CHB in the fetus are expensive there is a need of a marker to distinguish 
mothers with increased risk getting a child with CHB. It has been shown that mothers 
to children with AV block have an autoantibody profile associated with a high level of 
antibodies directed against a definite peptide stretch, corresponding to aa 200-239, in 
the Ro52 protein, which is also called the leucine zipper region. This peptide region has 
been synthesized into a peptide denoted p200, which has been demonstrated as a 
serologic marker for fetal risk of CHB (Salomonson 2002). 
 
3.1 PAPER I 
This study investigated the context of transferred maternal Ro52-p200 autoantibodies 
during pregnancy and postnatally, and what implication breast-feeding have on NLE 
manifestations such as skin involvement or postnatal progression of AV-nodal disease, 
during the infants first year in life. Breast milk contains protecting antibodies but is also 
a possible source of Ro52 IgG, IgA and IgM autoantibodies. This study prospectively 
followed a cohort of 30 children with or without CHB, and 21 of these children were 
breast-fed. 
 
3.1.1 Maternal – fetal autoantibody transfer 
All the women in the study were Ro52/SSA positive and as in previous studies 
(Salomonsson 2002, Strandberg 2008) Ro52-p200 levels were statistically significantly 
higher in pregnancies with a development of AVB II and III than in pregnancies 
resulting in a normal AV conduction. Concerning Ro60 and La antibody levels no 
significant differences were detected. These results also correlate to a previous Finnish, 
Swedish and American cohort study (Strandberg 2008). Clancy and colleagues have 
claimed that p200 antibodies do not show an increased level or a specificity correlated 
to children with CHB. But on the other hand their assay was performed in a different 
way (Clancy 2005), which is of great importance because p200 loses its antigenecity if 
the fold and structure are disrupted (Ottoson 2005). On the other hand no significant 
differences in Ro52-p200 antibody levels were measured between mothers to children 
with AV block I or AV block II/III, which might be an indication of a similarity 
between these two groups concerning the initiation of AV block. However, the 
difference may be due to certain factors involved in the susceptibility of the 
immunological reaction taking place in the heart conduction system. 
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3.1.2 Maternal IgG autoantibodies 
The majority of the maternal sera contained IgG antibodies recognizing Ro52, Ro60 
and La and these antibodies were also in the fetal circulation at birth, confirming 
maternal IgG transfer to the fetus. Though considering the differences when comparing 
the ELISA results of maternal autoantibody Ro52 and p200 IgG levels, it might be due 
to the different assay protocols or a difficulty in calibrating the corresponding 
amount/concentration between full length Ro52 and the p200 peptide. In addition, the 
affinity may differ between the Ro52 protein and the biotin labeled peptide. The result 
is however consistent between the two antigens. The Ro60 and La autoantibody levels 
were not significantly different between mothers with AVB children and healthy 
children, which is in agreement with previous studies (Salomonsson 2002, Julkunen 
2004, Fritsch 2005). 
 
3.1.3 Fetal clearance of maternal autoantibodies 
The fetal antibody titer was followed from birth and one year ahead. The test results 
show an apparent and relative fast clearance of IgG autoantibodies already at 4-5 weeks 
of age, which corresponds approximately to a normal maternal antibody half-life. This 
relative short time of possible detection of autoantibodies verifies that the major source 
of maternal autoantibodies is disrupted after placental detachment despite that more 
than 70% of the infants were breast-fed. 
 
3.1.4 The implication of breast-feeding in NLE symptom 
Askanase and colleagues have shown IgA and IgG autoantibodies specific to Ro52, 
Ro60 and La in breast milk (Askanase 2002). It is a disadvantage that our study has no 
data concerning immunoglobulin content from the breast milk of the participating 
mothers. On the other hand the maternal antibody levels in infant sera were of 
significantly lower levels indicating that autoantibodies in breast milk do not contribute 
substantially to titers established in utero. So, the symptoms associated to NLE are 
rather related to the placental IgG transfer and probably during a time in the 
development when the fetus is at its most vulnerable state. 
 
3.1.5 Immunoglobulin clearance and reversal of AV block 
NLE skin manifestations are associated with anti-La-antibodies and the mothers of 
children with NLE had significantly higher La IgG levels. We could see a 
normalization of the AV conduction time in three neonates with AV block type I, 
which was in parallel with the decrease of the maternal antibody levels in the infant 
sera. This additionally strengthens the meaning of placental transfer of maternal 
autoantibodies. The decrease of IgG titer may have nothing to do with the 
normalization of the AV conduction time among AV block I children - it is possible 
that the normalization already started in utero in the sense that these children did not 
express the specific susceptibility that is needed in the development leading to AV 
block III. So, perhaps the parallel occurrence of immunoglobulin clearance and the 
reverse of AV block I is due to confounding and should not at all be interpreted with 
the reverse of AV block I. 
The placental transfer of maternal autoantibodies is the primary influencing factor in 
the development of CHB or other NLE manifestations, which is also established due to 
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the decrease of maternal autoantibody levels in sera belonging to breast-feed infants. 
Simultaneously, breast-feeding does not delay a conversion from AV block I to normal 
conduction. In other words, there are no reasons not to advise Ro/SSA-, La/SSB 
positive women to breast-feed their children. 
We could not notice any significant difference in duration of breast-feeding regardless 
it was AV block children or healthy children. Although the number of participants in 
the cohort is too small to make any far reaching conclusion, the duration of breast-
feeding indicates an interesting trend concerning that > 70% of the AV block II/III 
children were breast-feed in ≤ 2 months while > 70% of the healthy children were 
breast-feed in ≥ 2 months, which makes it tempting to speculate that the duration of 
breast-feeding correlates to the children’s condition i.e. a healthy child will be breast-
feed a longer time. The children with AV block I follow the same pattern as the healthy 
children. 
 
3.2 PAPER II 
Despite a strong association between anti-Ro/SSA-La/SSB antibodies and CHB, > 85 
% of mothers to a child with AV-block are autoantibody positive, there is still a relative 
low risk (2 %) for these women to get child with CHB (Buyon 2004). It has been 
claimed there is a 33% incidence of AV block type I in utero, but due to the 
spontaneous reversal it is suggested that the clinical meaning is of less importance 
(Sonesson 2004). However, these results have been questioned by others (Buyon 2005, 
Rein 2005). Because some 20% of following pregnancies of Ro/SSA La/SSB positive 
mothers with a previous AV block child develops into a further CHB, there are strong 
indications that additional factors are involved in the development of CHB. The genetic 
importance in the development of CHB has been discussed (Siren 1999). This study 
point out how allelic variations of genes in the MHC complex determine both the 
maternal ability to form pathogenic antibodies as well as the fetal susceptibility to 
maternal autoantibodies in the context of CHB development. 
 
3.2.1 Experimental animal model 
To study the implication of different MHC and non-MHC genes in the development of 
CHB we used an established animal model with immunization of Ro52 protein in rats 
to induce CHB in the pups. The included rat strains have shown susceptibility for 
induction of other autoimmune diseases like experimental autoimmune 
encephalomyelitis (EAE) (Weissert 1998), and collagen-induced arthritis (CIA) 
(Lorentzen 1996, Griffiths 1993). This study was designed in purpose to investigate 
what influence MHC (RT1) and non-MHC genes have on different inbreed strains and 
MHC congenic rats. Three strains shared the same MHC haplotype RT1avl (DA, 
PVG.AV1 and LEW.AVl), and one strain (LEW) shared the background genes with the 
congenic LEW.AV1 strain, but distinguished in the MHC genes, because the native 
RT1 locus of the LEW strain is L (RT1l). The immunizations of rats were according to 
an established model (Figure 4). 
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After immunization of all rat strains (DA.AV1, PVG.AV1, LEWAV1 and LEW.L) 
Ro52-p200 antibodies were detected by ELISA, but with differing antigenic fine 
specificity. It has been shown that Ro52-p200 antibodies from mother of children with 
CHB have a different binding prophile to mutated p200 peptides than do Ro52-p200 
antibodies from non-CHB mothers (Ottosson 2005). Similar results were shown in this 
study – RT1av1 rats generated Ro52 antibodies with higher specificity to the same 
mutated p200 peptide pOUT, corresponding to the leucine zipper region, compared to 
rats of RT1l haplotype. That imply that Ro52 immunization generate antibodies 
towards Ro-52 and p200 irrespective of haplotype, but a decisive difference between 
RT1avl and RT1l haplotypes seems to be associated with the antibody fine specificity in 
AV block induced by Ro52 immunization. This was shown both due to the ability of 
antibody binding to mutated p200 peptides as well as their diverged pathogenic 
implication in the development of AV block - mothers of RT1avl got pups with 
developed PR prolongation, which did not happen to pups of RT1l mothers. This result 
confirmed previous studies regarding the ability of Ro52 autoantibody epitope binding 
specificity (Ottosson 2005), and a clear indication of the implication of maternal MHC.  
Because all rats with the same MHC haplotype RT1av1, regardless of strain or different 
non-MHC genes (DA, PVG.AV1 och LEW.AV1), got pups with PR prolongation, and 
the frequency of PR prolongation between the strains is fairly equal showing a non-
significant difference. This indicated that MHC haplotype AV1 determined the 
resulting significant PR prolongation compared to the MHC haplotype L. 
 
3.2.2 Different binding properties between AV1 and L haplotypes 
Rats express two different MHC class II molecules, RT1.B (orthologous to human 
HLA-DQ) and RT1.D (orthologous to human HLA-DR), and as we set out to decide 
each contribution of RT1.B and RT1.D molecules in the context of generating p200 T 
cell responses. In addition, the class II molecule RT1-B has a dominating role in 
generation of specific Ro52-p200 responses. It has also been shown that RT1-B express 
a larger allelic diversity compared to RT1-D (Saar 2008) and a greater ability to 
regulate the pathogenic development followed by an immunization (Strandberg 2008b). 
To decide what MHC molecule was dominating we used antibodies blocking either 
RT1.B (Ox-6) or RT1.D (Ox-17) in T cell lines from LEW.AV1 stimulated with p200 
Figure 4. Ro52 immunization 
model. Rats were immunized 
and then mated 2-4 weeks after 
last boost. ECG was performed 
on pups within their first 24 
hours. 
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peptides. The proliferation- and IFNγ production assays demonstrated a dominant role 
for RT1.B. Since AV1 and L strains generated Ro52-p200 antibodies with diverging 
fine specificity the question was whether AV1 or L haplotype strains also express 
RT1.B MHC class II molecules with differing peptide binding ability. And the results 
showed a considerable difference in the peptide binding cleft, electrostatic as well as 
conformational, resulting in different peptide presentation. This could be one of the 
important factors that differ among Ro52 positive women – they all have Ro52 
antibodies, but with different fine specificity i.e. heart block inducing properties. 
When analyzing p200 specific T cells we confirmed the usage of different TCRBV 
among RT1avl and RT1l respectively. We could conclude that T cell lines of RT1av1 and 
RT1l rats expressed different TCRBV; a dominance for TCRBV1 in AV1 and a 
dominance for TCRBV7 in L haplotype. This also indicates a diverging fine specificity 
since both B and T cell responses in Ro52 immunized LEW.AV1 and LEW.L rats 
differ, and the different TCRBV in each strain relates to different peptide presentation 
by the MHC class II. The difference in maternal MHC haplotype is of crucial 
significance in regulation of pathogenic antibody specificity, and these heart block 
inducing antibodies are linked to a dominant RT1av1 trait. 
 
3.2.3 An F2 cross reveals that the RT1l MHC haplotype increase the 
susceptibility to AV block in rat pups 
Previous studies have shown that autoantibodies specific for p200 peptides in Ro52 are 
associated to an increased risk of fetal CHB (Strandberg 2008, Salomonsson 2002). But 
still, the risk is relative low and the associations to additional involved factors in CHB 
development strong, which makes it difficult to use the maternal p200 antibody profile 
as a prognosis tool. CHB development is associated to different haplotypes between the 
mother and the child. The allelic differences coding for class II antigen presenting 
properties, make important divergences in T cell specificity and specific antibody 
binding properties. The difference in p200 peptide specificity between RT1av1 and RT1l 
strains and the lower frequency of AV block in RT1l pups could be due to insufficient 
pathogenic maternal RT1l Ro52 antibodies or a fetal resistance among RT1l pups. 
Due to evaluating whether heart block mainly is dependent on maternal or fetal factors 
we performed an F2 cross between AV block susceptible LEW.AV1 rats and heart 
block resistant LEW.L rats. Prolonged PR intervals were detected in F1 heterozygous 
RT1av1/l and monozygous RT1l pups, and the significant results show that the fetal 
haplotype is of significant importance due to susceptibility of maternal Ro52 
antibodies. In addition, the p200 antibody profile of binding pOUT and pZIP was the 
same in immunized F1 heterozygous females as it was in the previous immunization 
study involving RT1av1 rats, which confirmed consistency. This F2 cross study 
consisting of RT1avl and RT1l rats did show that the MHC haplotype in pups was of 
decisive importance in the implication of the regulating susceptibility of heart block 
development. Moreover, it appears to be of significance if the RT1l MHC is maternally 
rather than paternally inherited to the off-spring – pups of Ro52 immunized 
heterozygous F1 rats had significantly longer PR intervals if those rats consisted of 
maternal RT1l and paternal RT1avl compared to pups from Ro52 immunized rats 
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consisted of maternal RT1avl and paternal RT1l. However, only monozygotic RT1avl 
and RT1l pups were analyzed.  
  
3.2.4 Ro52 serum transfer confirms the association of MHC with fetal 
susceptibility to AV block 
In order to confirm the association of MHC encoded genes with fetal susceptibility to 
AV block, RT1av1 DA rat serum were transferred i.p. to RT1av1 (DA) and RT1l (LEW) 
rats. The serum was pooled from Ro52 immunized RT1av1 rats (DA) (n=10). The assay 
showed that maternal MHC restricts the production of specific pathogenic antibodies, 
but the fetal haplotype decides the AV block development once maternal antibodies are 
transferred into the fetal circulation. 
Pups of RT1av1 haplotype had the same heart rate as controls. Notably, maybe the assay 
should have had a control with no transferred serum at all just to have a complete 
normal baseline to compare with. According to the results of anti-Ro52- and p200 
antibody levels, pups of both RT1av1 and RT1l haplotypes showed high levels. The anti-
Ro52-antibody levels were equal between RT1av1 and RT1l while the anti-p200-
antibody levels were slightly lower in pups with RT1l haplotype. These results may 
verify the suggestion - if the fetal genetic condition exists to develop AV block, the 
susceptibility is enough regardless of the Ro52 antibody level. When we compared 
Ro52 antibody levels in pups from the immunization study with Ro52 antibody levels 
in pups from the transfer study, much higher levels were measured in pup serum from 
the immunization study, which seems reasonable because immunization will influence 
the whole immunologic system in the rat.  In addition, it also shows that the antibody 
level is not of that importance per se inducing AV block. The AV block development is 
rather dependent of a synergy between maternal anti-Ro52-antibody specificity and the 
fetal vulnerability as a consequence of the genetic susceptibility. 
These results also support the theory of AV development described by Wahren-
Herlenius and Sonesson (Wahren-Herlenius 2006) (Figure 5). 
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Figure 5. The two stage mechanism underlying the development of CHB (Adapted 
from Wahren-Herlenius 2006). In a first step, transplacentally transferred maternal 
Ro and La autoantibodies bind to cardiomyocytes and dysregulate calcium homeostasis 
leading to calcium overload and a following apoptosis. The apoptotic cells expose 
intracellular antigens to La autoantibodies. In a second step, genetically susceptible 
fetuses will develop a spread inflammatory reaction due to the antibody depositions and 
a further developed fibrosis and calcification into a resulting third-degree AV block 
(AV block III). Fetuses with no susceptible genes will not get any conduction damage 
and the clinical manifestations reverse spontaneously. 
 
3.2.5 Upregulated genes in congenital heart block 
As the genetic influence is assumed to be strongly associated to influencing the heart 
block development, AV block affected pup hearts were analyzed aiming to identify 
specific genes in the RT1l 20p12 MHC locus. There was a difference in 36/86 SNPs 
between AV1 and L haplotypes in the MHC locus. 
Besides HLA-DMB, which is seen as a candidate gene in the MHC locus implicating a 
role in the regulation of the differential susceptibility(Litsey 1985, Clancy 2004), there 
are at least four more genes in the MHC locus: TRIM26, ATP6G2, Bat5 and G7c 
(Table 1). 
 
Gene Aliases Function 
HLA-DMB  A possible key component 
involved in the antigen 
presentation (Jensen 1999). 
TRIM26 ZNF173, RNF95, AFP Function in immune 
regulation and as a viral 
restriction factor (Nisole 
2005). 
ATP6G2  Transmembrane protein, 
subunit of the vacuolar 
ATPase H+ pump, regulate 
the pH of the cell (Nishi 
2002). 
Bat5 HLA-B, associated 
transcript 5 
Transmembrane protein, 
α/β hydrolase, biological 
role unknown (Lehner 
2004). 
G7c C6, f27 Unknown function, 
suggested role in 
extracellular interactions 
(Kummanovic 2001). 
 
Table 1. Upregulated genes in the RT1l 20p12 MHC locus in congenital heart 
block. Identified upregulated genes in pup hearts after Ro52-positive transfer and 
suggested functions. 
 
TRIM26 is a homologue of Ro52 (TRIM21), and the proteins share the tripartite motif 
with a ring domain, a B-box and a coiled-coil motif as well as a B30.2 domain (Chu 
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1995, Reymond 2001, Espinosa 2006, Ottosson 2006, Hennig 2005). TRIM26 is like 
Ro52 predicted as an E3 ligase, but the target for TRIM26-mediated ubquitination is 
still not identified. 
The five above mentioned genes may be candidate genes involved in the pathogenesis 
of CHB either as targets for pathogenic heart block inducing autoantibodies or in the 
regulation of cellular mechanisms involved in the progress of heart block development. 
Exploring and identification of specific genes linked to experimental animal disease 
models increase the possibilities to find candidate genes in human patients. Since the 
techniques in exploring and interpret the function and the implication of genes and 
proteins are in progress, the methods to analyze are becoming faster, simpler and 
relative cheap to use, the easier it will be to identify new candidate genes. This is of 
importance in rare diseases because the populations to investigate are too small to give 
reliable information. Maybe these results could be part of the explanation why only a 
few neonates of Ro52 positive women get AV block – the origin of the MHC is one of 
the factors involved in the fetal susceptibility to develop AV block. 
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4 CONCLUSIONS 
In the study comprising paper I, “Serologic follow-up of children born to mothers with 
Ro/SSA autoantibodies”, we aimed to investigate the implication of maternal anti- 
Ro52-p200 antibodies and their association to NLE. Also, we studied if maternal Ro52 
IgA and IgM autoantibodies in breast-milk influence the progress of NLE 
manifestations in the skin or the progress of AV-nodal disease. 
We found that maternal autoantibodies decrease rapidly in the infant circulation during 
the first few weeks of life and that non-detectable levels were reached at one year of 
age. The autoantibody levels were rapidly decreased among breast-fed infants as well. 
This indicates that breast-feeding does not delay the reversal of AV block I to normal 
conduction. 
We further found that refraining from breastfeeding does not prevent NLE skin lesions. 
Hence, we found no reason not to recommend breastfeeding to Ro/La autoantibody 
positive mothers. 
Further, demonstrated in paper II, “Maternal MHC regulates generation of pathogenic 
antibodies and fetal MHC-encoded genes determine susceptibility in congenital heart 
block” our aims were to find additional risk factors contributing to CHB development 
in animals. We hypothesized that the susceptibility to CHB was related to the fetal 
genetic background. 
We found that maternal MHC restricts the pathogenic specificity of anti-Ro52 
antibodies, while the fetal susceptibility to develop CHB is determined by a different 
set of MHC-encoded genes. This indicates that the fetal genetic background is the main 
factor that determines the disease outcome in Ro52-positive pregnancies and explains 
why the majority of recurrent pregnancies do not lead to CHB affected children.  
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Serologic follow-up of children born to mothers
with Ro/SSA autoantibodies
R Klauninger1, A Skog1, L Horvath1, O Winqvist2, A Edner3, K Bremme3, SE Sonesson3 and M Wahren-Herlenius1
1Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden; 2Clinical Immunology Unit, Department of Medicine,
Karolinska Institutet, Stockholm, Sweden; and 3Department of Women and Child Health, Karolinska Institutet, Stockholm, Sweden
Neonatal lupus erythematosus (NLE) develops in foetuses of mothers with Ro/SSA and La/SSB
antibodies and may include foetal atrioventricular block and dermatologic manifestations. In this
study, we investigated postnatal Ro and La IgG, IgA and IgM antibody levels up to 1 year of age in
32 children born to Ro/SSA positive mothers. Antibody levels were correlated with NLE manifes-
tations, and the role of breast feeding in transfer of autoantibodies from mother to child was evalu-
ated. Ro52, Ro60 and La IgG antibodies all transferred from the mothers to their foetus in utero
and were present in the infant at birth as detected by enzyme-linked immunosorbent assay using
recombinant antigens and a synthetic peptide. A significant decrease in Ro52, Ro60 and La IgG
autoantibody levels of the infants was observed from birth to 4–5 weeks of age (P < 0.05, P < 0.05
and P < 0.01). Ro- and La-specific IgA and IgM antibodies were detected in the serum from a
subset of mothers. However, Ro- and La-specific IgA and IgM antibody levels were low or non-
detectable in children raised both with and without breastfeeding. Furthermore, NLE skin lesions
developed independently of breastfeeding. Our findings support a role for placental materno-foetal
transfer of IgG autoantibodies in the pathogenesis of NLE and indicate that refraining from breast-
feeding does not protect from NLE skin involvement. Lupus (2009) 18, 792–798.
Key words: congenital heart block; neonatal lupus; Ro52; SSA
Introduction
Pregnant women with Ro/SSA and La/SSB autoanti-
bodies are at risk of having children with neonatal
lupus erythematosus (NLE).1 The syndrome may
present with skin rash, liver involvement and cytope-
nias, as well as isolated congenital heart block.2,3 The
mothers are often diagnosed with systemic lupus
erythematosus (SLE) or Sjögren’s syndrome but may
also be asymptomatic. The foetal atrioventricular
(AV) block that develops between 18th and 24th
week of gestation after placental transfer of Ro/SSA
autoantibodies from the mother to the foetus4 may be
initiated as a first degree block.5 Immunoglobulin and
complement deposits are found in the foetal heart, and
after mononuclear cell infiltration, fibrosis and calcifi-
cation of the cardiac tissue, the block progresses to a
complete third degree AV block (AVB).6,7
Both Ro60 and La antibodies have been implicated
in the pathogenesis of congenital heart block, but
there is accumulating evidence that the Ro52 anti-
bodies are the initiating autoantibodies mediating
the heart block.8–12 More specifically, antibodies
recognising amino acid (aa) 200–239 (p200) of Ro52
were shown to bind the cell surface of cardiomyocytes
and induce dysregulation of intracellular calcium and
eventually induce cell death.13 Further, prolongation
of the foetal AV-time relates to the level of maternal
antibodies specific for the 200–239 aa stretch of
Ro52.13
The complete congenital heart block develops
in 2% of foetuses of Ro/SSA positive mothers14 and
is associated with a substantial mortality of
20–30%.4,15,16 The less severe first degree AVB is
detected in up to one-third of foetuses of Ro52-
positive pregnancies and may revert spontaneously
during the third trimester or the first few weeks after
birth.5 The levels of Ro52-p200 antibodies in the child
postnatally have not been investigated. Further, the
contribution of breastfeeding to Ro52 IgA and IgM
autoantibody levels postnatally in the child has not
been analysed, or whether breastfeeding puts the
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child at risk for Ro/SSA- and La/SSB-related manifes-
tations such as skin involvement or postnatal progres-
sion of AV-nodal disease. To evaluate neonatal lupus
symptoms and autoantibody levels postnatally in
infants born to mothers with Ro/SSA antibodies, we
prospectively followed a cohort of 32 children with or
without congenital heart block with frequent serum
sampling and clinical follow-up during their first year
of life.
Patients and methods
Patients
A total of 30 mothers and their 32 children were
included in the study. Two mothers had two consecu-
tive pregnancies with resulting children included. In
all, 10 mothers were diagnosed with Sjögren’s syn-
drome,17 18 mothers with SLE,18 1 with rheumatoid
arthritis19 and 3 did not fulfil criteria for rheumatic
disease. The pregnancies were followed with Doppler
echocardiography at the Pediatric Cardiology Unit at
Astrid Lindgren Children’s Hospital as previously
described.5,20 In all, 27 pregnancies were recruited
for foetal surveillance based on the presence of mater-
nal Ro/SSA antibodies and risk of congenital heart
block, whereas 5 pregnancies were referred after
signs of complete AVB had already been observed.21
All newborn infants were followed up with at least a
clinical cardiac examination and an electrocardio-
gram (ECG) after birth. Healthcare records were
available from 30 infants and used to collect data on
skin involvement and breastfeeding. A child was con-
sidered as breastfed when this was the sole intake of
nutrition.
Serum was sampled from the mothers during late
pregnancy (n = 30) or at the time of labour and from
the infants/children at birth from the cord (n = 16), at
3 days of age (n = 16), at 4–5 weeks (n = 22), at
6 months (n = 3) and at 1 year (n = 14). Sera were
stored in aliquots at −70 °C until use. The human
ethics committee at the Karolinska University Hospi-
tal approved the study, and informed consent was
obtained from the parents.
Recombinant proteins and synthetic peptide
Recombinant Ro52, Ro60 and La proteins were
expressed in Escherichia coli as previously described
using the pMAL vector (New England Biolabs,
Beverly, Massachusetts, USA) with maltose-binding
protein (MaBP) as fusion partner.22 Wild type MaBP
was used as control. Full-length proteins and MaBP
were purified on amylose columns according to the
manufacturer’s instructions (New England Biolabs).
Protein concentrationswere determinedwithBradford
protein assay (Bio-Rad, Richmond, Virginia, USA).
Synthetic p200 peptide including aa 200–239 of Ro52
was synthesised by Thermo Biosciences (Ulm,
Germany) with biotin conjugated at the N-terminal
end. Peptide purity was confirmed by high perfor-
mance liquid chromatography andmass spectrometry.
Enzyme-linked immunosorbent assay for
detection of maternal and infant antibodies to
recombinant Ro52, Ro60 and La proteins
Enzyme-linked immunosorbent assay (ELISA) was
performed as previously described23 with minor mod-
ifications. In short, medium-binding 96-well plates
(Nunc, Odense, Denmark) were coated overnight
(1 μg/well) with recombinant full-length Ro 52, Ro
60, La or wild-type vector MaBP protein diluted in
carbonate buffer (pH 9.6). Plates were blocked with
phosphate buffered saline (PBS)-0.05% Tween
(TPBS)/5% milk powder, and sera were tested at
1:1000 dilutions in TPBS/1% milk powder. Bound
antibodies were detected by affinity-purified alkaline
phosphatase (AP)-conjugated anti-human IgG anti-
bodies (Dakopatts, Glostrup, Denmark). Phosphatase
substrate tablets (Sigma, St. Louis, Missouri, USA)
dissolved in diethanolamine buffer (pH 9.6) were
used as substrate. The absorbance was measured at
405 nm. All steps were performed at room tempera-
ture except coating, which was performed at 4 °C. An
index was calculated based on a ratio with the serum
from one high titre patient selected as positive control
and with serum from one selected negative control;
recombinant protein-index = [(OD sample − ODneg-
ative control)/(OD positive control − OD negative
control)] × 100.
ELISA for detection of maternal and infant
antibodies to peptide p200
ELISA for detection of p200 binding antibodies was
performed as previously described.24 In brief, high-
binding 96-well plates (Nunc) were coated with
100 μL of 3 μg/mL streptavidin diluted in water.
Plates were incubated at +4 °C for 2 days and then
dried at 37 °C and stored at +4 °C until use. Plates
were washed four times with wash buffer (0.15 M
NaCl, ×0.006 M NaH2PO4.H20, 20% NaN3/0.05%
Tween-20/2% BSA) and unspecific binding blocked
with 200 μL 4% BSA in PBS. Plates were washed
once with PBS and coated at least 6 h at room tem-
perature with 100 μL of 3 μg/mL biotin-p200 peptide
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in coating buffer (0.03 MNa2CO3, 0.07 MNaHCO3,
0.1% NaN3). Plates were washed four times with
wash buffer. A total of 100 μL serum was added
per well at a dilution of 1:300, and plates were incu-
bated shaking at room temperature for 2 h. Plates
were washed four times and affinity-purified AP-
conjugated, rabbit anti-human IgG antibodies
(Dakopatts) were added at a dilution of 1:1000. Plates
were washed four times with wash buffer. Phospha-
tase substrate tablets (Sigma) were dissolved in
diethanolamine pH 9.8, and 100 μL/well was used
for detection of IgG. The absorbance was measured
at 405 nm using a Sunrise absorbance reader (Tecan,
Männedorf, Switzerland) and the Magellan V 3.11
software (Tecan, Männedorf, Switzerland). A p200
index was calculated based on a ratio with one high-
titre patient selected as standard where the p200
index = [(OD sample − OD negative control)/(OD
positive control − OD negative control)] × 100. All
p200 assays in this study were run in the same
laboratory, Department of Clinical Immunology,
Karolinska University Hospital.
Statistical analysis
Statistical analysis was performed using Statistica
7.0 (Statsoft, Tulsa, Oklahoma, USA). The Mann–
WhitneyU-test was used to compare different groups,
and the Wilcoxon test was used to analyse longitudi-
nal data within individuals. The level of significance
was set at P < 0.05.
Results
Pregnancy and transfer of maternal Ro52, Ro60 and
La autoantibodies to the foetus
During the 32 included pregnancies, second or third
degree heart block developed in 6 children, first degree
heart block was detected in 7 children and in 19 chil-
dren no cardiac involvement was registered. The
majority of these cases have been clinically described
before.21 Of the six foetuses with AVB II/III, two
responded to steroid treatment and were born with a
first degree AVB. Of these, one had a normal ECG at
1 week of age, whereas the other still had an AVB I at
8 months. Of the seven foetuses with signs of AVB I in
utero, four had a normal ECG at birth and three had
an AVB I. The three neonates born with AVB I had
reverted to normal conduction within 4 weeks of age.
Maternal autoantibodies relate to the development
of congenital heart block, and to examine the correla-
tion between maternal and foetal anti-p200, anti-
Ro52, anti-Ro60 and anti-La IgG antibody levels,
sera were collected from mothers and children at
birth. As previously noted, p200 antibody levels were
higher in sera from mothers of children affected by
heart block than in sera from mothers of children
without cardiac involvement (Figure 1A and B).
Ro60 and La antibodies were also detected in most,
but not all, mothers of children with first or second/
third degree congenital heart block (Figure 1C and
D). Investigating sera from the neonates by antigen-
specific ELISAs showed that p200, Ro52, Ro60 and
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Figure 1 Autoantibodies to Ro52, Ro60 and La antigens in
mothers and their children. Antibody levels to p200 (A), Ro52
(B), Ro60 (C) and La (D) in the mothers were determined using
ELISA with recombinant antigen and synthetic peptides. Levels
of p200-Ro52 antibodies were higher in mothers of children
with AVB II/III than in mothers of children with normal sinus
rhythm (P < 0.05), whereas Ro60 and La antibody levels were
not significantly different. All autoantibody specificities were
transferred from the mother to the foetus (E) p200, (F) Ro52,
(G) Ro60 and (H) La as determined by ELISA with
recombinant antigen and synthetic peptides.
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La IgG antibodies were all transferred to the children
(Figure 1 E–H).
Clearing of maternal IgG Ro52, Ro60 and La
antibodies from the circulation of the infant
The infants were followed clinically and serologically
during their first year of life. Serum was sampled at
birth, at 3–4 days of age, at 4–5 weeks, at 6 months
and at 1 year of age. Transferred maternal p200,
Ro52, Ro60 and La IgG antibodies were continuously
depleted from the circulation of the infant (Figure 2).
At 4–5 weeks of age, p200 antibody levels were signif-
icantly lower than at birth (P < 0.001). Also Ro52,
Ro60 and La antibody levels had decreased signifi-
cantly at 4–5 weeks of age compared with levels at
birth (P < 0.05, P < 0.05 and P < 0.01, respectively).
In the infants with first degree heart block at birth, this
decrease in autoantibody levels was parallel with nor-
malisation of the AV interval. Antibody levels contin-
ued to decrease, and at 1 year of age, no child had
detectable maternal autoantibodies (Figure 2).
Ro52, Ro60 and La IgA and IgM antibodies
in mothers and children
IgG is the dominating immunoglobulin isotype of
Ro52, Ro60 and La antibodies, but IgA and IgM
Ro/La antibodies have also been shown in
patients.25,26 Although IgG is actively transported
across the placenta and reaches the foetus in utero,
IgA and IgM isotypes do not cross the placenta. How-
ever, immunoglobulin transfer from the mother to the
infant via breast milk during lactation is a further
potential source for autoantibodies in the child after
birth, including autoantigen-specific IgA and IgM. In
Sweden, the tradition for breastfeeding is strong and
the majority (21/30) of mothers in our study fed their
babies by breast milk alone for the first 8 weeks, and
most of them longer (Figure 3). We observed that
there was no significant difference in the duration of
breastfeeding in relation either to foetal diagnosis
(P > 0.05) or to maternal diagnosis (P > 0.05).
Serum samples from the mothers and their children
at 4–5 weeks of age were analysed by ELISA for IgA-
and IgM-specific antibodies recognising Ro52, Ro60
and La antigens to investigate the degree of foetal
uptake via breast milk and whether breastfeeding
increased the risk for postnatal neonatal lupus symp-
toms. Several mothers had IgA or IgM antibodies
recognising the Ro52, Ro60 or La autoantigens, but
all infants had low or non-detectable levels of the cor-
responding IgA and IgM autoantibodies at 4–5 weeks
of age (Figure 4). Serum levels were equally low in
breastfed and non-breastfed children. However, IgA
or IgM Ro52, IgA Ro60 and IgA and IgM La anti-
body levels were significantly higher in mothers of
foetuses with AVB I-III compared with mothers of
foetuses with normal conduction (P < 0.03, in all
cases).
NLE skin lesions developed in five infants (16%).
Maternal IgA and IgM Ro52, Ro60 or La antibody
levels were not significantly associated with develop-
ment of skin lesions in the neonate. Interestingly, how-
ever, anti-La IgG antibody levels were significantly
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Figure 2 Clearing of Ro and La autoantibodies from the
circulation of the infant. Levels of p200, Ro52, Ro60 and La
antibodies were investigated in samples taken at birth (cord
blood), at 3–4 days, 4–5 weeks, 4–6 months and 1 year using
ELISA with recombinant antigens and synthetic p200 peptide.
Figure 3 Breastfeeding period of infants born to Ro52-antibody
positive mothers. Period (months) of breastfeeding postnatally of
children included in the study. Foetal cardiac diagnosis is
indicated as atrioventricular block (AVB) I and AVB II/III.
Maternal rheumatic diagnosis is indicated as SLE, Sjögren’s
syndrome (SS) or other. NSR: normal sinus rhythm.
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higher in mothers of children who developed skin
lesions (P < 0.02). Of the infants who developed
NLE skin lesions, one child was breastfed for
4 months, two were breastfed for 2 months and two
were not breastfed. Thus, skin lesions appear not to
depend on the baby being breastfed.
Discussion
Foetal exposure to Ro/SSA and La/SSB autoantibo-
dies may lead to development of NLE. During preg-
nancy, maternal IgG autoantibodies are transported
to the foetus via placenta, whereas breast milk is a
potential source of autoantibodies for the infant after
birth. To investigate levels of postnatal autoantibodies
in infants born to Ro/SSA positive mothers and their
correlation to NLE manifestations, we followed a
cohort of 32 children from birth to 1 year of age
with frequent serum sampling and clinical follow-up.
All included mothers were Ro/SSA positive, and as
has been previously shown,11,24 Ro52-p200 levels were
higher in pregnancies where AVB II or III developed
than in pregnancies where the foetus had normal AV
conduction. Sera from the majority of the mothers
contained IgG autoantibodies recognising all three
heart block-associated autoantigens Ro52, Ro60 and
La. All three autoantibody specificities were trans-
ferred to the neonate, and they were present in the
circulation of the infants at birth. Transfer of Ro52
autoantibodies of IgG subclasses has previously been
described, and a predominance of IgG1 was shown in
the foetus.27 After birth, the foetal levels of Ro and La
IgG autoantibodies, including p200 antibody levels,
rapidly decreased and were significantly lower at
4–5 weeks of age. The infantile decrease of IgG auto-
antibodies is in accordance with the half-life of
circulating immunoglobulins, suggesting that after
placental detachment, the source of immunoglobulins
is markedly decreased or ended. The decrease in auto-
antibody levels occurred despite that breast milk was
the only ingest for at least 1 month in more than 70%
of the infants.
Breast milk may also contain IgA and IgM antibo-
dies and has been shown to contain IgA and IgG auto-
antibodies specific for Ro52, Ro60 and La.28 In our
study, a subset of mothers had IgA or IgM antibodies
binding Ro52, Ro60 and La antigens. Although
breast milk from Ro/La antibody positive mothers
has been described to contain IgA and IgG specific
for Ro52, Ro60 and La,28 the levels of Ro52-, Ro60-
and La-specific IgA and IgM were low or not detect-
able in infants of our study at 4–5 weeks of age. At the
later time points of infant serum sampling in our
study, all specific IgA and IgM antibody levels were
non-detectable (data not shown). Thus, although the
maternal milk may contain autoantigen-specific IgA
and IgM antibodies, it appears that the dose or foetal
uptake is not enough to make the infant seropositive.
Further, also IgG antibodies specific for Ro and La
antibodies decreased rapidly in all infants although
the majority of the children were breastfed, emphasis-
ing the predominant role of placental materno-foetal
transfer of antibodies in supplying the foetus with spe-
cific immunoglobulins. However, a significant corre-
lation of IgA or IgM Ro52, IgA Ro60 and IgA and
IgM La antibody levels was noted in mothers of foe-
tuses with AVB I-III compared with mothers of
foetuses with normal conduction. As IgA and IgM
antibodies do not cross the placenta and are not
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Figure 4 Ro52, Ro60 and La IgM and IgA autoantibodies in mothers and their infants. Levels of Ro52, Ro60 and La IgA and IgM
autoantibodies were determined by ELISA in maternal samples and samples from infants at 4–5 weeks of age.
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present in the neonate at birth, the correlation of
autoantigen-specific maternal IgA and IgM antibo-
dies with heart block in the foetus is probably rather
a reflection of the maternal autoreactive immune
system per se than directly causative of congenital
heart block.
Because NLE skin lesions occurred in five of the
children, we correlated the skin manifestations with
breastfeeding. We found that NLE skin lesions devel-
oped both in breastfed and in non-breastfed infants, as
was observed also by Askanase et al.28 Even if the
numbers are limited, these observations suggest that
breast feeding is not involved in the development of
skinmanifestations. These findings are in line with our
findings that breast milk is not a predominant source
of transfer of heart block-associated autoantibodies.
Therefore, the pathogenesis of NLE skin lesions is
likely to be coupled to the placental transfer of auto-
reactive antibodies recognising skin-specific epitopes,
and our data indicate that La antibodies may be
involved in inducing NLE skin lesions as mothers of
infants with NLE skin lesions had significantly higher
La IgG levels.
The decrease in autoantibody levels in three neo-
nates affected by first degree AVB at birth without a
history of higher degree of block was paralleled by
normalisation of AV conduction time. This is in
accordance with the findings of Cimaz et al.,29 who
described concomitant disappearance of ECG abnor-
malities and Ro52 and Ro60 autoantibodies in infants
without congenital heart block (CHB) born to
Ro/SSA positive mothers. These findings further
underscore a role of materno-foetal transfer of auto-
antibodies in affecting the foetal cardiac conduction
system because disappearance of the maternal auto-
antibodies from the foetal circulation led to normal-
ised foetal conduction in cases were a permanent
damage had not developed.
Our results show that maternal autoantibodies in
the infant decrease rapidly during the first few weeks
of life and have reached non-detectable levels at 1 year
of age. The antibody levels decrease also in breastfed
infants, and breast feeding does not appear to delay
conversion from AVB I to normal conduction. Fur-
ther, refraining from breastfeeding did not prevent
NLE skin lesions, and our interpretation is that there
is no reason not to recommend breastfeeding to
mothers with Ro/La autoantibodies.
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ABSTRACT  
 
Congenital heart block develops in fetuses of Ro52-antibody positive women. The heart block 
inducing autoantibodies are transferred to the fetus during pregnancy and affect the developing heart. 
A subsequent fetus may however not be affected, despite the presence of maternal autoantibodies. 
This indicates that there are additional, yet unidentified, factors critical for development of congenital 
heart block. Here we demonstrate that besides the maternal MHC controlling antibody specificity, 
congenital heart block depends on fetal susceptibility, which is determined by fetal MHC-encoded 
genes. Using MHC congenic rat strains we show that heart block develops in rat pups of three strains 
carrying MHC haplotype RT1
av1
 (DA, PVG.AV1 and LEW.AV1) after maternal Ro52 immunization, 
while pups from LEW rats (RT1
l
) rarely developed block. Different anti-Ro52 antibody fine-
specificities were generated in RT1
av1
 versus RT1
l
 animals. Maternal and fetal influence was 
determined in an F2 cross between LEW.AV1 and LEW strains, which revealed higher susceptibility 
in RT1
l
 than RT1
av1 
pups once pathogenic Ro52-antibodies were present. This was further confirmed 
in that RT1
l
 pups more frequently developed heart block than RT1
av1
 pups after passive transfer of 
RT1
av1
 anti-Ro52 sera, and by microarray analysis of fetal hearts that revealed increased expression 
of distinct MHC-encoded genes in RT1
l
 compared to RT1
av1
 pups. Our findings suggest that 
generation of the pathogenic Ro52 antibodies is restricted by maternal MHC, and that a different set 
of genes encoded by the fetal MHC locus regulate susceptibility and determine the fetal disease 
outcome in anti-Ro52 positive pregnancies. 
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INTRODUCTION 
 
Pregnancy in autoimmune conditions is often marred by complications, and the fetus may be directly 
affected by maternal autoantibodies to develop neonatal lupus, myastenia or hypothyroidism. 
Congenital heart block is a potentially lethal manifestation of the neonatal lupus syndrome, which 
develops in fetuses of rheumatic women with Ro52 autoantibodies (1). In the rheumatic mothers, 
production of Ro52-antibodies has been repeatedly linked to MHC class II DRB1*03 alleles (2, 3). 
During pregnancy, the maternal autoantibodies cross the placenta and bind cardiomyocytes in the 
heart, in which the atrioventricular (AV) conduction system is disrupted by inflammation with 
subsequent fibrosis and calcification leading to a complete AV block (4, 5). Immunization of mice or 
rats with Ro52 or Ro52-derived peptides leads to AV block in the offspring, and these animal models 
have been used to define the nature and quality of the pathogenic autoantibodies that mediate heart 
block (6, 7).  
The vast majority of mothers of infants with congenital heart block carry Ro52 antibodies, but 
the risk for heart block in a single Ro-positive pregnancy is only 1-2% (8, 9). In mothers who have 
children with congenital heart block, the risk for an affected child is increased to 20% in subsequent 
pregnancies (10), but heart block does not always develop despite persisting maternal anti-Ro52 
autoantibodies (11). Although maternal autoantibodies are crucial in the development of fetal heart 
block, the clinically observed recurrence rate of 20% suggests that additional factors are critical for 
establishing the heart block. Maternal disease severity and infections during pregnancy have been 
investigated as potential risk factors, but were not found to contribute to the congenital heart block 
(12-14).  
To address the hypothesis that susceptibility may relate to the genetic make-up of the fetus 
itself, we used the Ro52 immunization-induced animal model of congenital heart block to study the 
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role of different MHC (RT1) and non-MHC genes in susceptibility to the heart block in various rat 
strains. Our data demonstrate that production of Ro52-antibodies with pathogenic specificity was 
restricted by maternal MHC, while a different set of MHC-encoded genes in the fetus conferred 
increased susceptibility to congenital heart block and determined the disease outcome in Ro52-
positive pregnancies. 
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RESULTS AND DISCUSSION 
 
Maternal MHC regulates generation of pathogenic antibody-specificities inducing heart block 
Genetic influence has been implied in the development of congenital heart block (15), but has 
not been explored experimentally. To define the contribution of MHC and non-MHC genes, various 
rat strains that differed in MHC and background genes were immunized with Ro52 and fetal heart 
block assessed in the newborn pups by ECG. In a pilot study, two strains, DA (RT1av1) and LEW 
(RT1l), differing in both MHC and non-MHC genes were investigated. The strains have previously 
been shown to differ in their susceptibility to other induced autoimmune diseases such as EAE (16) 
and collagen-induced arthritis (17, 18). Congenital heart block developed three-fold more often in 
pups of the DA strain than in LEW pups (data not shown), and a study was therefore designed to 
dissect the influence of MHC and non-MHC genes by use of several inbred strains and MHC 
congenic rats (Supplemental Table 1).  
Rats of four different strains were included. Three shared the same MHC haplotype RT1
av1
 
(DA, PVG.AV1 and LEW.AV1), and the fourth strain (LEW) shared the background genes with the 
congenic LEW.AVI strain, but differed in the MHC genes, as the native RT1 locus of the LEW strain 
is L (RT1
l
). After Ro52-immunization of rat females and mating (Figure 1A), first-degree AV block 
developed in 45% of the DA (RT1
av1
) pups, 44% of the PVG.AV1 and 47% of the LEW.AV1 pups. 
However, only 10% of pups in the LEW (RT1
l
) group developed AV block (Figure 1B). Rats from 
each strain immunized with control protein (maltose-binding protein, MaBP) showed no heart block 
development (Figure 1B). The pups of Ro52 immunized animals in the three rat strains sharing the 
RT1
av1
 haplotype (DA, PVG.AV1, LEW.AV1) had significantly longer PR intervals than did the 
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LEW (RT1
l
 ) pups (p<0.001), while there was no significant difference in PR-intervals between the 
three RT1
av1
 carrying strains (Figure 1C and D). 
Induction of congenital heart block depends on the presence of specific pathogenic 
autoantibodies binding to an epitope within the stretch of amino acid (aa) residues 200-239 (p200) of 
Ro52 (7). To analyze whether the difference in development of congenital heart block between 
RT1
av1 and RT1l haplotype carrying strains related to the level or specificity in produced Ro52-
binding antibodies, sera from the pups and mothers were analyzed using ELISA with p200 peptide 
and mutated p200 peptides (Figure 1E and F). The mutated peptides denoted pZIP and pOUT were 
generated to distinguish binding specificty of antibodies to different epitopes within the 40 aa p200 
peptide (7), and mutated amino acids are indicated in Figure 1E and F.  Titers of antibodies binding 
the p200 peptide of Ro52 did not differ between strains or animals affected or not by heart block 
(Figure 1G, H), but notably the binding specificity of Ro52-p200 immunization-induced antibodies 
differed between rats with RT1av1 and RT1l MHC alleles as demonstrated by differential affinity to 
the mutated p200 peptides pZIP and pOUT (Figure 1I). This indicates that although both RT1av1 and 
RT1
l bearing strains generate p200 binding antibodies in response to Ro52 immunization, maternal 
MHC restricts the fine specificity of the generated antibodies.  
To investigate the mechanism relating to generation of different p200 immune responses in 
the LEW RT1av1 and RT1l strains, we first determined the relative role of MHC class II molecules in 
AV1 carrying strains in generating T cell responses. The rat has two major MHC class II molecules; 
RT1.B (orthologous to human HLA-DQ) and RT1.D (orthologous to human HLA-DR). p200-
specific T cell lines from LEW.AV1 rats were stimulated by p200 in the presence of  
antibodies blocking RT1.B (Ox-6) or RT1.D (Ox-17). Using proliferation assays and IFN-γ 
formation in ELISPOT, we could clearly demonstrate a dominant role for RT1.B in activation of 
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AV1-derived p200-specific clonal T cells, since blocking with Ox-6 significantly inhibited the T cell 
responses and Ox-17 antibodies had little effect on proliferation or IFN-γ production (Figure 2A and 
B).  
The RT1.B α and β chains for AVI and L have been sequenced (19, 20), and an alignment 
suggested several critical differences in both α and β chains (Figure 2C). Molecular models of the 
peptide binding clefts of RT1.B AV1 and L (Figure 2D) were created based on their sequence 
homology to the MHC class II molecules I-A
u
 , I-A
b
 and HLA-DR4 (21-23). A comparison of the 
molecular models of RT1.B AVI and L reveal several important structural and electrostatic 
differences within the peptide-binding cleft, suggesting that the peptide repertoire bound and 
presented by RT1.B AVI will differ from RT1.B L. The most important modifications are localized 
within and around the P1 pocket (Figure 2D), used by most MHC class II molecules as a major 
anchoring site (24). The phenylalanine and the positively charged lysine residues at position 28 and 
35 of the α-chain of RT1.B AVI are replaced by a histidine and a negatively charged glutamate, 
respectively, in the RT1.B L. Thus, the composition of the structural and electrostatic properties of 
the P1-pocket will differ between RT1.B AVI and RT1.B L. Furthermore, the β-chain glycine residue 
at position 26 in RT1.B AVI is modified to a larger negatively charged aspartate that points towards 
the middle section of the peptide binding cleft, most probably interacting with peptide residue p4 in 
the antigenic peptide. Finally, important structural and electrostatic modifications are present in the 
C-terminal part of the peptide binding clefts of RT1.B AVI and L, affecting the pocket that interacts 
with the peptide residue p9. Here, the negatively charged β-chain residue aspartate 57 in RT1.B AVI 
is replaced by a serine in RT1.B L, while surrounding residues such as α-chain residues T69 and L76 
in RT1.B AVI are substituted to two isoleucines in RT1.B L. In conclusion, the structural and 
electrostatic differences observed in N- and C-termini as well as within the middle section of the 
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peptide binding clefts of RT1.B AVI and L suggest that the peptide-binding motifs of the epitopes 
bound to the two MHC class II molecules will be different, and that the conformation of most 
peptides bound in the two clefts will also differ. Ultimately the sequential and structural comparison 
suggests that different peptides will be preferentially presented by the AV1 and L RT1.B MHC class 
II molecules. 
To analyze the functional impact of these potentially important differences in peptide 
presentation we performed an analysis of the T cell receptor usage by TCRBV spectratyping of p200 
specific T cell lines from LEW.AV1 and LEW rats. Our analysis showed that the TCRBV usage is 
different between LEW.AV1 and LEW strains in p200 specific T cell lines. The most striking 
difference was the dominant use of TCRBV1 in LEW.AV1-derived p200 specific T cell lines not 
observed in T cells lines from Lew.L animals, and a clear expansion of a single peak in TCRBV7 
suggestive of a clonal expansion in Lew.AV1 which was not observed in the T cell lines from LEW 
animals (Figure 2E and Supplemental Figure 1). The TCRBV1 and 7 spectratypes were normally 
distributed in naïve T cells from both strains (Supplementary Figure 1), and constitute less than 1% 
and 2% respectively of the total TCRBV repertoire in naïve Lewis rats (25). 
From these experiments we conclude that the fine specificities of both B and T cell responses 
in Ro52-immunized LEW.AV1 and LEW rats differ, and that generation of T cells with different 
specificity and TCRBV usage most probably relates to differential peptide presentation by the MHC 
in LEW.AV1 and LEW strains.  
 
Increased susceptibility to AV block in rat pups is dominantly inherited and associated with the 
MHC RT1
l
 allele  
The specificities of generated anti-p200 antibodies differed between RT1av1 and RT1l strains,  
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and the lower frequency of AV block in RT1l pups could thus depend either on a lack of generation 
of pathogenic anti-Ro52 antibody specificities in RT1l rat mothers, or fetal resistance in RT1l pups to 
disease. In order to differentiate whether the observed MHC-linked effects in the development of 
heart block were due to maternal or fetal factors, we performed an F2 cross between the susceptible 
LEW.AV1 rat strain and the resistant LEW rat strain (Figure 3A). LEW.AV1 and LEW rats were 
mated, and the F1 heterozygous females (RT1av1/l) were immunized with Ro52. These F1 females 
were then mated with heterozygous F1 males (RT1av1/l) to produce homozygous RT1av1, RT1l or 
heterozygous RT1av1/l offspring. Genotyping of the F2 generation pups revealed that RT1 haplotype 
frequencies were 23% RT1av1, 23% RT1l, and 54% heterozygous RT1av1/l. ECG was performed at 
birth to detect heart block in the pups of Ro52-immunized mothers. Analysis of prolonged PR 
intervals with respect to the pup genotype revealed that a homozygous RT1l or heterozygous RT1av1/l 
genotype in the pup correlated with significantly higher PR intervals than in homozygous RT1av1 
pups (p<0.05) (Figure 3B, C). This indicates that the MHC allele RT1l in the pups in fact confers a 
higher susceptibility to heart block induced by Ro52 antibodies than RT1av1 alleles in the pup. From 
this follows that the findings of the immunization study of DA, PVG.AV1, LEW.AV1 and LEW rats 
did indeed depend on a difference in maternal MHC haplotype regulation of pathogenic antibody 
specificity, and not fetal resistance in LEW pups. 
 The p200 antibody binding profile in the heterozygous RT1av1/l Ro52-immunized rats in the 
F1 generation was similar to that of the RT1av1 rats on the three backgrounds DA/PVG/LEW (Figure 
3D), indicating that generation of pathogenic heart block inducing antibodies is a dominant RT1av1-
linked trait. We also noted that pups descendent from F1 parents with L/AV1 x L/AV1 had more 
affected conduction than pups descendent from AVI/L x AV1/L parents (Figure 3E, p<0.01, RT1av1 
and RT1l homozygous pups only), and that pups which inherit LL from the maternal founder rather 
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than ll from the paternal founder have longer PR intervals (Figure 3F, p<0.001 Mann-Whitney U-
test). This suggests an additional layer of epigenetic regulation of congenital heart block, as 
previously indicated for other autoimmune conditions (26, 27). 
 In all, the data from the F2 cross demonstrate that generation of maternal pathogenic heart 
block-inducing Ro52 antibodies is a dominant trait linked to the RT1av1 MHC haplotype, and that 
pups with RT1l alleles are more susceptible to the cardio-pathogenic effects of these autoantibodies. 
 
Congenital heart block is induced in RT1
l
 pups following transfer of RT1
av1
 Ro52-immune 
serum to pregnant RT1
l
 rats 
 To directly investigate the increased susceptibility to develop heart block in pups with RT1l 
alleles compared to pups with RT1av1 alleles, we generated Ro52-immune serum in RT1av1 rats (DA) 
for transfer experiments. Sera from 10 immunized animals were pooled for transfer, and non-immune 
serum from RT1av1 rats (DA) was used as a control in parallel transfer experiments. Two ml of serum 
were given i.p. to homozygous pregnant RT1av1 (DA) or RT1l (LEW) rats on day 6 and 9 of 
pregnancy, and ECG was recorded from the pups at birth. Also in this experimental setting, using 
passive transfer of Ro52 antibodies generated in RT1av1 rats, the RT1l pups displayed higher 
susceptibility to pathogenic Ro52 antibodies and had longer PR intervals than RT1av1 pups (Figure 
4A). Transfer of Ro52 antibodies to the pups was confirmed by ELISA using pup serum (Figure 4C 
and D). Transfer of increasing amounts of p200 specific antibodies induced heart block also in AV1 
pups (data not shown), but at the lower antibody levels used in our transfer experiments and 
compared to the immunization model (Figure 4E and F), it was clear that pups with RT1l MHC are 
more susceptible to congenital heart block (Figure 4A). In all, our results demonstrate that higher 
susceptibility to heart block development is linked to the RT1l MHC haplotype in the pups. 
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Specific genes linked to fetal susceptibility for congenital heart block 
 To identify specific genes linked to fetal susceptibility for congenital heart block, we first 
analyzed the genetic differences in the L and AV1 RT1 loci. Using microsatellites, the LEW.AV1 
congenic rat was defined by a <7Mb region at the telomeric end of chromosome 20 originating from 
the AV1 haplotype (Figure 5A), and the L and AV1 loci differed in 36 of 86 investigated SNPs 
within this interval (28), Figure 5B. The identified polymorphisms are not randomly dispersed 
throughout the RT1 locus, but 3-4 clusters were observed, Figure 5B. This suggests that factors 
relating to the different susceptibility in the two strains may be encoded by genes located in, or not 
far from, the SNP clusters.  
 To identify specific MHC-encoded genes with altered expression linked to the difference in 
fetal susceptibility in AV1 and L animals, we performed microarray mRNA expression analyses of 
hearts from LEW and LEW.AV1 pups of mothers that had received normal non-immune or anti-
Ro52 positive serum (AV1-derived) in passive transfer. A comparison of the expression of MHC-
encoded genes in RT1
l and RT1av1 pups where the mother received control serum only, revealed that 
the non-classical HLA-DMb and RT1-T24-1 genes were upregulated in LEW pups compared to 
LEW.AV1 pups at p<0.0005 (data not shown). HLA-DMb was the most highly upregulated gene 
with a ratio of 4.1 LEW/LEW.AV1, emphasizing that even at the basal level there are important 
differences in the expression of these MHC-encoded genes between the two strains. The difference in 
expression of these two genes further increased in hearts from RT1
l and RT1av1 pups of mothers that 
had received anti-Ro52 positive immune serum, and HLA-DMb was five-fold higher expressed in 
LEW compared to Lew.AV1 (p<0.0005) in pups from mothers receiving anti-Ro52 positive serum 
(Figure 5C). We also identified four additional non-class I or II MHC-encoded genes (Bat5, TRIM26, 
G7c, ATP6v1G2) with an increased expression at p<0.0005 in LEW pups compared to LEW.AV1 
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pups, though the highest difference was still in the expression of HLA-DMb (Figure 5C). One gene, 
Clic2, was downregulated in LEW pups compared to LEW.AV1 pups after transfer of Ro52-positive 
serum. All genes with increased expression in RT1
l
 pups after either normal serum or Ro52-positive 
serum treatment observed by microarray analysis were re-confirmed also by quantitative RT-PCR 
(Figure 5D and E). Down-regulation of Clic2 was not confirmed by the PCR analysis (Figure 5E). 
 In addition to MHC-encoded genes, a set of genes outside the 20p12 locus were also 
differentially expressed between the two strains. These were functionally annotated and 
predominantly belonged to the immune system, signaling and metabolic processes (Supplemental 
Figure 2), and may reflect secondary changes in expression patterns after disease onset. Notably, 
HLA-DMb however remained the most differentially expressed gene between the two strains at 
p<0.0005, even at the genome-wide analysis. These data functionally identify HLA-DMb as one of 
the possible candidate genes within the MHC locus that may regulate the differential susceptibility 
observed between the LEW and LEW.AV1 pups in mediating congenital heart block development. 
However, there are at least five additional genes within the MHC locus not belonging to classical 
MHC class I or II, that are differentially expressed in the two strains in response to the pathogenic 
anti-Ro52 antibodies.  All of these genes are potential candidates that may be mediating differential 
susceptibility.  
 In conclusion, our study confers strong evidence that allelic variants of genes within the MHC 
complex both affect the maternal ability to form pathogenic antibodies, as well as the fetal 
susceptibility to develop congenital heart block in response to these antibodies. Our data further show 
that these traits are linked to different alleles in the mother and the child, respectively. We 
demonstrate that maternal MHC-linkage is essential in generation of pathogenic antibodies by allelic 
differences in class II antigen presenting properties, also causing subtle differences in T cell 
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specificities. The class II genes of the RT1
av1
 and RT1
l
 haplotypes have also previously been 
characterized with regard to their different peptide binding spectra of both the RT1.B and D 
molecules (29), and the pathogenicity of the immune response following immunization with myelin 
antigens (30). Fetal susceptibility to the passively transferred antibodies related to a different MHC 
haplotype, and interestingly also in human patients the production of Ro52-antibodies is strongly 
linked to specific maternal MHC - A1, B8, DR3B1*03 (2, 3, 31) - while these particular maternal 
alleles are rarely present in the affected children (15, 32). Rather, human fetal susceptibility has been 
suggested to relate to HLA-Cw*03 (15). In addition to MHC-mediated effects, our studies also 
indicate an epigenetic influence in fetal susceptibility to congenital heart block, as has been observed 
for other autoimmune conditions (26, 27).  
 The rat MHC-complex encodes at least 220 genes (33),  and we identified a specific 
upregulation of HLA-DMb along with five more genes in the susceptible RT1
l
 strain in heart block 
development. HLA-DMb facilitates removal of the CLIP peptide and stabilizes the peptide-empty 
MHC class II molecules while the repertoire of peptides is selected for binding, and may thus be of 
great importance in the developing fetal inflammation which disrupts the atrioventricular conduction 
system in the affected heart and leads to the complete AV block (4, 5).  
 In summary, our findings show that generation of the pathogenic Ro52 antibodies is restricted 
by maternal MHC, while a different set of MHC-encoded genes in the fetus regulate susceptibility 
and determine the fetal outcome in Ro52-positive pregnancies. 
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MATERIALS AND METHODS  
 
Experimental animals 
DA (RT1av1), LEW.AV1 (RT1av1) and LEW (RT1l) rats were originally obtained from the 
Zentralinstitut for Versuchstierzucht (Prof. Hans Hedrich, Hannover, Germany). After introgressing 
the DA RT1av1 into the LEW strain, animals were backcrossed for 16 generations. PVG.AV1 
(RT1av1) rats were originally obtained from Harlan UK Limited (Blackthorn, UK). Animals were 
kept and bred in the animal facility at the Center for Molecular Medicine at the Karolinska Institutet. 
All experimental protocols were approved by the Stockholm North Ethics Committee. 
 
Recombinant proteins and synthetic peptides 
Recombinant Ro52 protein was expressed from the pMAL vector (New England Biolabs) as a 
fusion to maltose binding protein (MaBP) or from the p6xHis vector and purified as described (34, 
35).  Wild-type MaBP protein was expressed from the pMAL vector and purified as described (34). 
Ro52 peptides p200, pZIP and pOUT were purchased from Thermo BioSciences.  
 
Immunizations, serum transfer and ECG recordings 
Six-week-old rats were immunized with 100 µg Ro52 protein in complete Freund's adjuvant 
and boosted three times with 50 µg Ro52 protein in incomplete Freund's adjuvant. Rats were mated 
2-4 weeks after last boost. On the day of delivery, three-lead electrocardiograms (ECGs) were 
recorded from conscious pups using four microelectrodes attached to a body clip (36). ECGs were 
sampled for 5 seconds four times per minute with a sampling rate of 1000 Hz. The ECG was 
digitalized and analyzed with Pharmlab (AstraZeneca). QRS-complexes were averaged and used to 
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calculate the PR-interval. AV block I was defined as the average of PR-intervals in control animals 
+2SD.  
For serum transfer and microarray experiments, anti-sera were generated by the same 
protocol. Control sera were from non-immunized animals. Rats were injected i.p. with 2 ml serum on 
day 6 and 2 ml serum on day 9 of pregnancy.  
 
ELISA for detection of Ro52 protein and peptide antibodies 
ELISA was performed as described (7, 34) using p200 peptide and His-tagged Ro52. Rat sera 
were tested at a dilution of 1:500 (immunization studies) or 1:50 (serum transfer experiments), and all 
at 1:50 when comparing levels. 
 
Generation of T cell lines 
Female LEW.AV1 (n=4) or LEW rats (n=4) were immunized with 100 µg Ro52 protein in 
complete Freund's adjuvant at the base of the tail and draining lymph nodes removed on day 14 post 
immunization. Single cell suspensions were generated and cells cultured with restimulation using p200 
peptide (10 µg/ml) and syngenic APCs in three rounds interspersed with IL-2 supplemented T cell 
medium to generate clonal T cells as previously described (37). 
 
T cell proliferation and ELISPOT assays 
T cell lines were plated with syngenic APCs in parallel sets of round-bottomed 96-well plates in 
culture medium with either concavalin A (5 µg/ml), p200 peptide (10 µg/ml) or p200 peptide with Ox-
6 and/or Ox-17 (38) antibodies (10 µg/ml). After 48h cells were either pulsed for 16 h with 1 µCi 
[3H]thymidine per well and proliferation measured as counts per minute using a microplate liquid 
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scintillation counter (Wallac MicroBeta TriLux; PerkinElmer), or IFN-γ production analyzed in 
ELISPOT as previously described (39). Cells were incubated in the anti-rat IFN-γ pre-coated 
nitrocellulose plates for 20h, and spots were analyzed using an Elispot plate-reader (AID Elispot 
Reader System).  
 
Molecular modelling of the peptide binding clefts of RT1.B AVI and RT1.B L 
Sequence alignment was performed using the program BioEdit 
(http://www.mbio.ncsu.edu/BioEdit/). Molecular models of the peptide binding clefts of RT1.B-AVI 
and RT1.B-L were created on the basis of their sequence homology to classical MHC class II 
molecules, using the SWISS-MODEL Protein Modeling Server (40). The crystal structures of HLA-
DR4 (PDB code 1D5Z), I-A
b
 (1MUJ) and I-A
u
 (2PXY) were used as templates for the modelling. 
The coordinates of both models will be provided upon request. All figures were created using the 
program PYMOL (http://pymol.sourceforge.net/). 
 
TCRBV spectratyping 
Total RNA was extracted from T cell lines using an RNeasy mini kit (Qiagen). Reverse 
transcription was performed with random hexamer primers and Superscript reverse transcriptase 
(Invitrogen). The PCR was performed as previously (41)with 23 published individual TCRBV 
primers specific for TCRBV1-20 and a common 6-FAM labelled CB primer (41). The product was 
separated in capillary electrophoresis and analyzed by the Genescan software v3.7 (Applied 
Biosystems).   
 
Polymorphic markers and genotyping of animals in the F2 cross 
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Genomic DNA was prepared from tail tips (42). D20Wox17, D20Wox18, D20Rat21, 
D20UW1, D20Rat41, D20Rat45, D20Mgh4, D20Rat50, D20Rat31, D20Rat33, D20Rat7 and 
D20Rat6 (http://rgd.mcw.edu/), covering 27.4 Mb of telomeric end of chromosome 20, were used to 
establish the borders of AV1 congenic interval and for subsequent typing of F2 rats. The SNP map of 
the AV1 and L RT1 loci was adapted from (28). Genotyping in the F2 cross was performed using 
three markers polymorphic for the MHC region between AV1 and L (D20Rat41, D20UW1 and 
D20Rat21). Primers were purchased from Proligo. PCR amplification was performed as previously 
described (43) with [γ-33P]ATP end-labelling of the forward primer and using the following 
thermocycling protocol: initial denaturation at 94°C for 13 min, followed by 30 cycles of 94°C for 
30s, 55°C for 1 min and 72°C for 1.5 min, followed by a final extension period at 72°C for 7 min. 
PCR products were size fractionated on 6% polyacrylamide gels and visualized by autoradiography. 
All genotypes were evaluated manually by two independent observers. 
 
Microarray analyses 
RNA from fetal hearts was purified using the TRIzol reagent (Invitrogen) followed by 
RNeasy Mini kits (Qiagen). The Agilent 2100 Bioanalyzer (Agilent Technologies) was used to 
confirm integrity of the RNA. RNA was prepared for microarray analysis using the whole transcript 
sense target labeling protocol (Affymetrix) and Rat Gene 1.0 ST arrays used to profile mRNA levels 
from individual subjects. The scanned output files were analyzed using the Affymetrix GeneChip 
Command Console. In the Expression consol (v1.1), background correction was performed by PM-
GCBG, data normalized by Global Median and resulting data were summarized using the PLIER 
software. Gene expression was compared by student’s unpaired t-test and the level of significance set 
to p<0.0005. 
 Fetal susceptibility to congenital heart block 18 
 
Real-time PCR 
RNA from fetal hearts was purified using the TRIzol reagent (Invitrogen) followed by 
RNeasy Mini kits (Qiagen). The Agilent 2100 Bioanalyzer (Agilent Technologies) was used to 
confirm integrity of the RNA. Reverse transcription was performed with random hexamer primers 
and Superscript reverse transcriptase (Invitrogen). The primers used are defined in Supplemental 
Table 2. A SYBR Green–based protocol was applied (44), and PCR products were analyzed by 
melting curve analysis to confirm a single product. The mRNA levels were calculated using the 
standard curve method and normalized to HPRT mRNA. 
 
Statistical analysis 
 Statistical analysis for experiments other than microarray analysis was performed using 
Statistica 7.0 (Statsoft, Tulsa, OK, USA). Non-parametric analysis with Mann-Whitney U-test and 
ANOVA was used. The level of significance was set at p < 0.05.  
 
Online supplemental material 
 Table S1 details strains and animal number used in the study, Table S2 specifies non-classical 
MHC encoded genes identified in micoarray experiments and defines primers used in RT-PCR. 
Figure S1 illustrates TCRVB1 in naïve T cells and T cell lines from RT1av1 and RT1l derived Ro52-
p200 specific T cell lines. Figure S2 shows analysis of microarray data and functional annotation of 
genes.    
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FIGURE LEGENDS 
 
Figure 1. A Ro52 immunization rat model demonstrates association of RT1
av1
 with 
development of AV block. (A) Ro52 and p200 antibody levels in DA (RT1av1), PVG.AV1, 
LEW.AV1 and LEW (RT1l) rats pre- and post-immunization with Ro52-MaBP or control MaBP 
protein. (B) PR values for DA, PVG.AV1, LEW.AV1 and LEW rats by litter in rats immunized with 
Ro52-MaBP or control protein MaBP. 45% DA, 44% PVG.AV1, 47% LEW.AV1 and 10% LEW rat 
pups developed AVB I. Hatched lines indicate +2SD from the mean of each control group (PR 
mean±SD: MaBP-DA 57.3±3.2; MaBP-PVG.AV1 55.6±2.7; MaBP-LEW.AV1 53.4±4.6; MaBP-
LEW 52.0±4.2). (C) Pups from Ro52-immunized rats with MHC haplotype AV1 had significantly 
longer PR intervals than pups from Ro52-immunized rats with MHC haplotype L, p<0.0001. (D) 
There was no significant difference in PR intervals of pups from Ro52-immunized mothers of the 
three strains with the same MHC haplotype (AV1) but different non-MHC genes. (E) Schematic 
representation of the Ro52 protein and p200 peptide, with the p200 derived pZIP and pOUT peptide 
amino acid replacements indicated. (F) Ribbon-structure representation of the predicted pZIP and 
pOUT secondary structure fold visualizing the position of mutated amino acids (represented in red). 
(G) p200 antibody levels in Ro52-immunized AV1 and L rats and (H) p200 antibody units in healthy 
or AVB I affected pups. (I) pOUT and pZIP peptide binding in RT1av1 and RT1l rats. pZIP and 
pOUT binding is expressed normalized to p200 antibody levels for each serum. * p<0.05, ** p<0.01. 
 
Figure 2. The RT1.B peptide binding cleft and TCRBV usage in p200 specific clonal T cells 
differ between LEW RT1
av1
 and RT1
l
 rats. (A) Proliferation and IFN-γ spot formation after p200 
peptide (10 µg/µl) stimulation of p200-specific T cell lines generated from LEW.AV1 rats. 
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Antibodies Ox-6 (blocking RT1.B-mediated T cell activaton) or Ox-17 (blocking RT1.D-mediated T 
cell activation) were added to stimulation cultures (10 µg/µl), showing that the activation of p200-
specific clonal T cells is predominantly dependent on presentation via RT1.B. Data from p200 
specific T cell lines derived from four individual LEW.AV1 rats tested in triplicates are shown. (B) 
Alignment of the amino acid sequences encoding the α- and β-chains of the MHC class II molecules 
RT1.B-AVI and RT1.B-L. Conserved, identical amino acid blocks are shadowed grey, and amino 
acid positions that differ between the two strains are denoted in red (negatively charged), blue 
(positively charged), orange (polar) and green (hydrophobic). (C) Molecular models of the peptide-
binding clefts of the MHC class II molecules RT1.B-AVI and RT1.B-L are presented in the upper 
and lower panels, respectively, using schematic (left) and surface electrostatic (right) representations. 
Negatively and positively charged regions of the surfaces are given in red and blue, respectively, and 
a comparison of the molecular models suggest that large structural and electrostatic differences are 
present within the respective peptide-binding clefts of the AV1 and L RT1.B molecules within the 
P1, P4 and P9 pockets. Residues that potentially contact bound peptides and that result in the most 
important structural and charge differences within the peptide binding cleft of RT1.B-AVI and 
RT1.B-L are indicated. (D) TCRBV1 and 7 spectratypes in p200-specific T cell lines of RT1
av1 and 
RT1
l
 animals.  
 
Figure 3. A reciprocal F2 cross reveals MHC encoded genes (RT1
l
) confer fetal susceptibility to 
AV block. (A) Schematic organization of the F2 cross. Pups born were genotyped and found to be 
23% RT1av1, 23% RT1l and 54% heterozygous RT1av1/l. (B) Discrete PR values as measured by ECG 
at birth in pups with RT1av1, heterozygous RT1av1/l or RT1l genotype. (C) Pups with an RT1l 
haplotype have significantly longer PR intervals than pups with the RT1av1 haplotype (p<0.05, Mann-
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Whitney U-test) and pups with a heterozygous genotype also have significantly prolonged PR 
intervals compared to the RT1av1 pups (p<0.05, ANOVA and Mann-Whitney U-test). (D) ELISA 
with p200, pZIP and pOUT peptides with sera from F1 immunized female rats shows that F1 
heterozygous mothers have the same antibody binding profile (pOUT > pZIP) as found in the RT1av1 
rats from the immunization study. (E) Pups of Ro52 immunized L/AV1 x L/AV1 F1 rats had 
significantly longer PR intervals compared to pups from Ro52 immunized AV1/L x AV1/L F1 rats 
(p<0.01). Only homozygous RT1av1 and RT1l pups were included in the analysis. (F) Significantly 
longer PR intervals were also observed if the RT1l was inherited from the maternal founders (LL) 
than the paternal founders (ll) (p<0.001, Mann-Whitney U-test). There is however no difference in 
PR intervals when the RT1av1 haplotype is inherited from the maternal or paternal founder. * p<0.05, 
** p<0.01, ***p<0.001. 
 
Figure 4. A Ro52+ serum transfer model confirms association of MHC encoded genes with fetal 
susceptibility to AV block. Serum pooled from ten Ro52 immunized RT1av1 rats (DA) and control 
non-immune RT1av1 (DA) rat serum were transferred i.p. to RT1av1 (DA) and RT1l (LEW) rats day 6 
and 9 of pregnancy and ECG performed on pups at birth. (A) Discrete values of normalized PR 
intervals for RT1av1 and RT1l rat pups, from control and Ro52+ sera injected mothers. (B) RT1l pups 
had significantly longer PR intervals in pups born to rats injected with Ro52+ serum than those 
injected with control serum (p<0.001). (C) Ro52 and (D) p200 antibody levels in RT1av1 and RT1l 
pups born to mothers injected with anti-Ro52 positive sera or control sera. (E) Ro52 antibody levels 
in RT1av1 rat mothers from the immunization study and the pooled RT1av1 (DA) rat serum (n=10) 
which was used in the transfer model. (F) Levels of Ro52 antibodies in representative RT1av1 (DA) 
Supplemental Figure 1, Strandberg et al. TCRBV1 spectratype analyses in (A)
naive LEW.AV1 and LEW.L T cells presented both in the same scale as in (B), and
enlarged to visualize normal distribution. (B) TCRBV1 spectratype analyses in
p200 specific T cell lines derived from LEW.AV1 and LEW.L animals (n=4 and n=4,
respectively).
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Supplemental Figure 2, Strandberg et al. (A) Scatterplot of average gene 
expression of all genes analyzed by the Rat Gene 1.0 ST array in LEW (n=4) by 
LEW.AV1 (n=6) pup hearts after transfer of Ro52-positive serum. The non-classical 
MHC-encoded genes with an increased (red) or decreased (blue) expression 
(p<0.0005) in RT1l compared to RT1av1 are indicated by squares. (B) Functional 
annotation with grouping according to the Gene Ontology Annotation database 
(http://www.ebi.ac.uk/GOA/) of the genes from (A) with an increased or decreased 
expression in pup hearts at p<0.0005 in RT1l compared to RT1av1 after Ro52-
positive serum transfer.  
 Supplemental Table 1. Rat strains and MHC genotype in immunization, transfer and F2 cross 
studies. Both congenic and native RT1 loci are indicated. 
 
   
Ro52 immunization study # pups / strain.RT1  
      
Rats immunized with DA.AV1 PVG.AV1 LEW.AV1 LEW.L Total 
Ro52 49 48 51 49 197 
Control protein 26 8 28 26 88 
 
Serum transfer 
     
Rats injected with       
AV1 Ro52-immune serum 7   18 25 
AV1 non-immune serum 23   16 39 
      
F2 cross  LEW.AV1 x LEW.L # pups / F1 mating combination             
RT1 genotype of pups (AV1, AVI/L, L)                          
 
      
Rats immunized with 
AV1/L        
x AV1/L 
L/AV1     
x AV1/L 
AV1/L      
x L/AV1 
L/AV1   
x L/AV1 
Total 
Ro52 
 
45 
(13,24,8)      
46 
(12,25,9)      
48 
(7,26,15)         
21 
(4,12,5)          
160 
(36,87,37) 
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 Supplemental Table 2.  
MHC-encoded genes with increased or decreased expression (p<0.0005) in congenital heart block 
and primers used for quantitative real-time PCR. 
 
Symbol Name Gene 
Id 
Forward primer 
Reverse primer 
Atp6v1g2 ATPase, H+ transporting, V1 
subunit G isoform 2 
368044 5’-CAAGCAGCAGGCGGCCATGG-3’ 
5’-GAAGCTGAGTCAGGACTCGC-3’ 
Bat5 HLA-B associated transcript 5 361796 5’-GAAGCTGGTGATCTGC-3’ 
5’-AATGGTACCCCCGTGC-3’ 
Clic2 chloride intracellular channel 2 294141 5’-CTCGCTCCTCCAAGGTATCC-3’ 
5’-CGTTTAAATTCTCTAAGCAGAG-3’ 
G7c G7c protein 309611 5’-CTCCTTGCTGCCTCGCTACC-3’ 
5’-CACTGAGCTCCAGAAGCACG-3’ 
Hla-dmb major histocompatibility complex, 
class II, DM beta 
294273 5’-GACCCACAGAACCAGAACGC-3’ 
5’-CAAGCTGCCCGTTCTTCATCC-3’ 
RT1-T24-1 histocompatibility 2, T region locus 
24 
361787 5’-CTTTACCCGAACTGACCCTCC-3’ 
5’-GTCTCCACAAGCTCCATGTCC-3’ 
Trim26 tripartite motif protein 26 309586 5'-TGGTGGAGAAGGCTGC-3’ 
5'-TGCAGCTTCGTCAGTGC-3’ 
  

